National Society of Genetic Counselors

A LANDMARK IN GENOMICS:

OUR VALUE IN HEALTHCARE

35th Annual Education Conference

PROGRAM BOOK

SEPTEMBER 28 – OCTOBER 1, 2016

WASHINGTON STATE CONVENTION CENTER • SEATTLE, WA

white glove service for every specimen.



At Insight, we believe in a personalized approach to genetic testing.

Direct access to our licensed and board-certified genetic counselors, rare disease testing panels, custom gene sequencing and chromosome analyses are just some of the ways we can bring you...well, insight.

Looking for a different kind of lab experience? We're here to serve you.

Learn more about our lab services at InsightMedicalGenetics.com

visit us at booth #810

insight™
MEDICAL GENETICS

Table of Contents

WELCOME TO SEATTLE

On behalf of the National Society of Genetic Counselors (NSGC), the Annual Education Conference (AEC) Planning Subcommittee and the NSGC Board of Directors, thank you for joining us!

NSGC is celebrating this landmark time in genomics and the 35th anniversary of our AEC with education and networking designed to support your continued professional growth. Educational sessions will cover a variety of topics at the forefront of genomics such as somatic tumor testing, prenatal cell-free DNA screening and bioinformatics for genetic counselors. Educational highlights you do not want to miss include the pre-conference symposium, *The Genetic Testing Laboratory: Insider View for Genetic Counselors* (page 14) and our opening plenary sessions, *Population Based Screening for Inherited Predisposition to Breast and Ovarian Cancer* and *Gene to Community* and *Community to Action: The Power of Social Media* (page 14). Reference pages 14-21 for sessions submitted/sponsored by your NSGC Special Interest Group (SIG). Maximize your AEC experience by building your schedule around education sessions specific to your professional interests.

Invaluable experiences await you outside of the lecture room walls as well. Take advantage of the Welcome Reception, SIG meetings and the AEConnect area to network with more than 2,000 of your peers. Visit the Exhibitor Suite to see the latest product offerings and services within our profession. Catch up with friends and make new connections during this year's special 35th Anniversary Reception, program reunions and daily breaks. Attend the State of the Society Address and the SIG Fair to learn more about the latest efforts of your professional organization. Experience all of the incredible activities this week has to offer!

We hope you enjoy your time here in Seattle, absorbing content on the latest innovations and developments in the profession of genetic counseling, all while enjoying this amazing city!

Jason Flanagan, MS, CGC
2016 AEC Subcommittee Chair

Renee Chard, MS, CGC
2016 AEC Subcommittee Vice-Chair

Download the Official AEC Mobile App

NSGC delivers everything AEC directly to your fingertips via the 2016 NSGC AEC mobile app. View conference session descriptions, speakers and scheduling information. Use the interactive maps to navigate the Exhibitor Suite with ease, search the exhibitor directory and stay in the know with conference alerts. On your smartphone or tablet, search for "NSGC 2016 AEC" in your app store or direct your mobile browser to **www.nsgc.org/mobileapp**. Follow what others are saying or post your own insights on Twitter during the AEC using **#NSGC16**.

ABOUT THE 35TH ANNUAL EDUCATION CONFERENCE

Statement of Purpose

The 35th Annual Education Conference (AEC) focuses specifically on the educational needs of genetic counselors. The AEC addresses a wide variety of genetic counseling practice areas and provides the latest information for the genetic counseling profession. Attendees will gain important information to support and enhance their current practice by attending sessions such as: *Patient Safety in the Era of Genomic Medicine* and *Billing Integrity and Compliance and Legal Liability for the Genetic Counselor.* The Exhibitor Suite will provide current information and the opportunity to talk with exhibitors about new developments in genetics. The pre-conference symposia will provide in-depth information on specific topics relevant to the field of genetic counseling.

Continuing Education

NSGC has been approved to offer up to 32.25 Contact Hours at the AEC. CEUs earned through these activities will be accepted by the American Board of Genetic Counseling (ABGC) as Category 1 CEUs for purposes of certification and recertification. Individuals must be certified at the time of participation in the activity in order for it to count towards recertification.

Pre-conference Symposia	Earn up to:	5.00	Contact Hours
AEC General Sessions	Earn up to:	21.75	Contact Hours
Sponsored Meal Sessions	Earn up to:	5.50	Contact Hours
Total	**Earn up to:**	**32.25**	**Contact Hours**

IMPORTANT: NSGC will only be able to verify the credits you earned for the sessions for which you provide an attendance verification code and complete an evaluation in the online system.

Evaluation Process/Claiming CEUs

Individuals claiming CEUs MUST complete evaluations, however NSGC greatly appreciates feedback from all attendees. An attendance verification code will be provided in each session. See page 56 for a grid to assist you in tracking verification codes for the sessions that you have attended.

To complete your evaluations, follow these steps:

1 **Log in to the NSGC website**, and go to **www.nsgc.org/aecevaluations**.

2 **Click on the Evaluation link** to be directed to the evaluation website.

3. For each session, **add the attendance verification code (AVC)** that you received in the lecture room and then evaluate the session.

4 **Save each session as you go**, as the website will log you out after 10 minutes of inactivity. (If this happens, you must go back to the NSGC website and repeat steps 1 and 2 to log back in and re-enter any unsaved information.)

PLEASE NOTE: Although your responses to the individual session evaluation questions will save each time you click "Save and Continue" the AVC will need to be re-entered if you re-enter that session to edit your responses.

5. Once you have completed evaluations for all sessions attended, you will be able to **evaluate the overall conference** by selecting "Return to Registered Events."

6 **Review your evaluation** to make sure you claimed credit for each session you attended. Print and email your final certificate of credit earned for your records. Once you have printed your certificate, you will NOT be able to go back and edit any more sessions.

The deadline to complete your evaluations is December 1, 2016. Please contact the NSGC Executive Office at **nsgc@nsgc.org** if you need assistance.

NSGC will not be able to issue continuing education certificates if an evaluation is not completed by December 1, 2016. No exceptions will be made.

2016 AEC Session Recordings

Maximize your AEC experience: View sessions you missed in Seattle, earn additional CEUs and review the valuable information you gathered during the conference by purchasing online session recordings. The AEC recordings package will feature all pre-conference symposia, plenary and educational breakout sessions.* The online recordings will contain synced audio and PowerPoint presentations for each recorded session.

The full session recordings package, including both the pre-conference symposia and the AEC recordings, is available for a reduced price of $149 for all conference attendees.** Registered attendees will be able to order the AEC recordings through October 1, 2016, at the discounted rate, or following the conference at an increased rate. The AEC recordings package will be available to view in January 2017.

To earn Category 1 CEUs, it is required that you complete and pass a quiz included at the conclusion of each session.

Visit **www.nsgc.org/2016aec** or stop by the registration desk to add session recordings to your registration.

** With speaker approval*

*** Discounted package rates only available when purchased with a conference registration.*

Overall Conference Evaluation

To complete an evaluation of the overall conference, please follow the steps listed below:

1. Log in to the NSGC website, and go to **www.nsgc.org/aecevaluations**.
2. Click on the Evaluation link to enter the evaluation website.
3. Select the Overall/Post-event link to evaluate the conference.

GENERAL INFORMATION

Registration Hours

Washington State Convention Center – Atrium Lobby

Tuesday, September 27
5:00 PM – 8:00 PM

Wednesday, September 28
7:00 AM – 7:00 PM

Thursday, September 29
6:30 AM – 7:00 PM

Friday, September 30
7:00 AM – 7:00 PM

Saturday, October 1
7:30 AM – 1:00 PM

Exhibitor Suite Hours

Washington State Convention Center – Exhibit Hall 4AB

Wednesday, September 28
6:00 PM – 8:30 PM

Thursday, September 29
7:00 AM – 8:00 AM
5:00 PM – 7:45 PM

Friday, September 30
7:00 AM – 8:00 AM
11:15 AM – 3:00 PM
2:45 PM Passport to Prizes Drawing

Job Boards

Bulletin boards with push-pins are available at the AEConnect area in the Exhibitor Suite for attendees to post job opportunities. Other forms of advertising are not permitted. Material posted will be monitored and inappropriate information is subject to removal at NSGC's discretion.

Attendee List Information

Attendee lists were posted on the NSGC website prior to the conference and an updated list will be posted following the conference. Lists are available at the registration desk and are available for reproduction at the attendee's expense at the FedEx Office Print and Ship Center on Level 1 of the Washington State Convention Center. Attendee lists are provided solely for networking and may not be used for solicitation purposes. NSGC is not responsible for errors and/or omissions.

Handouts and Presentations

NSGC offers electronic versions of AEC session handouts when provided in advance by AEC speakers. A copy of the handouts will be available for reproduction at the attendee's expense at the FedEx Office Print and Ship Center on Level 1 of the Washington State Convention Center. All session handouts (if provided by the speaker) are posted on the NSGC website and will be available until March 1, 2017. To download handouts go to **www.nsgc.org/2016AECHandouts**.

To download pre-conference symposia handouts go to **www.nsgc.org/2016AECPCSHandouts**.

Business Center Hours

The FedEx Office Print and Ship Center is located on Level 1 of the Washington State Convention Center and is open during the following hours:

Monday – Thursday
7:00 AM – 10:00 PM

Friday
7:00 AM – 9:00 PM

Saturday – Sunday
9:00 AM – 6:00 PM

Internet Access

NSGC attendees will have wireless Internet available in all meeting spaces and common areas at the Washington State Convention Center. Internet at the Convention Center can be accessed by using the network **NSGC2016**. The password is **celebrate35**.

NSGC gratefully acknowledges our wireless Internet sponsor at the Convention Center:

sequenom

The Sheraton Seattle has provided complimentary wireless Internet in your guest rooms. Please request login information at the front desk.

Conflict of Interest Disclosures

All presenters at the AEC are required to disclose any conflicts of interest (COI) related to their presentation. To view these disclosures, visit **www.nsgc.org/2016disclosures**.

Sponsored Sessions

Sponsored meal sessions are available for pre-registration. If you pre-registered to attend a session, a ticket was printed with your badge. In order to be admitted to each session, please bring your conference badge and the ticket that pertains to that session. We encourage you to arrive early for each session to allow all attendees time to be seated. If you did not pre-register for a session but are still interested in attending, please stop by registration to check availability for each session.

Please note that not all attendees will receive food and beverage with their admittance. Please check your ticket to see if the sponsor will provide food, or if you are encouraged to bring your own.

Executive Office Information

NSGC Executive Office
330 N. Wabash Avenue, Suite 2000
Chicago, IL 60611 USA
Phone: 312.321.6834
Email: nsgc@nsgc.org
Website: www.nsgc.org

Executive Director
Meghan Carey
mcarey@nsgc.org

SCHEDULE-AT-A-GLANCE

KEY:

- Registration and Breaks
- Pre-Conference Symposia
- Plenary Sessions
- NSGC Commitee, SIG and Leadership Activities
- Exhibitor Suite
- Concurrent Papers/Poster Presentation
- Educational Break Out Sessions
- Sponsored Sessions
- Program Reunions

Wednesday, September 28

7:00 AM – 7:00 PM	Registration Open — *Atrium Lobby*					
7:00 AM – 8:00 AM	Pre-Conference Breakfast — *Ballroom 6ABC Lobby*					
8:00 AM – 2:00 PM	CEU Pre-Conference Symposia					
	A01 Double Dipping: Education Research in Diverse Settings *Room 603*	**A02** Integrating Oncology and Genomics for Patient Care and Management *Room 4C-3-4*	**A03** Oh the Places You'll Go! Genetic Counseling as a Fast Pass to Personal and Professional Growth *Room 604*	**A04** Opening the cfDNA Non-invasive Prenatal Screen Floodgates: Expansion into the General Population and Its Impact on Industry Counselors, Clinical Providers and Policy Makers *Room 611 - 614*	**A05** Religion and Spirituality in Genetic Counseling *Room 608 - 609*	**A06** The Genetic Testing Laboratory: Insider View for Genetic Counselors *Room 606 - 607*
10:15 AM – 10:30 AM	Pre-Conference Break — *Ballroom 6ABC Lobby*					
2:00 PM – 2:30 PM	NSGC SIG Fair — *Room 615 - 617*					
2:00 PM – 3:15 PM	AEC 101: Welcome to the Emerald City — *Room 618 - 620*					
3:30 PM – 3:45 PM	AEC Opening Remarks — *Ballroom 6ABC*					
3:45 PM – 4:45 PM	CEU **A07** Population Based Screening for Inherited Predisposition to Breast and Ovarian Cancer — *Ballroom 6ABC*					
4:45 PM – 5:45 PM	CEU **A08** Gene to Community, Community to Action: The Power of Social Media in Genomics — *Ballroom 6ABC*					
5:45 PM – 6:15 PM	SIG Meetings					
	ART/Infertility SIG *Room 307*	Cardiovascular SIG *Room 303*	Cystic Fibrosis SIG *Room 310*	Neurogenetics SIG *Room 602*	Student/New Member SIG *Room 603*	
6:00 PM – 8:30 PM	Welcome Reception in the Exhibitor Suite — *Exhibit Hall 4AB*					
6:15 PM – 7:30 PM	CEU **A09** Posters with Authors, Group A — *Exhibit Hall 4AB*					
8:00 PM	Various Program Reunions — see page 12 for more information					

Thursday, September 29

6:30 AM – 7:00 PM	Registration Open — *Atrium Lobby*	
7:00 AM – 7:45 AM	CEU B01 Reproductive Genetics and Hereditary Cancer Screening: A Legal Perspective **Sponsored by Integrated Genetics** — *Ballroom 6E*	
7:00 AM - 7:45 AM	SIG Meetings	
	Leadership and Management SIG Meeting — *Room 303*	Psychiatric SIG Meeting — *Room 602*
7:00 AM – 8:00 AM	Exhibitor Suite Open — *Exhibit Hall 4AB*	
7:00 AM – 8:00 AM	AEC Breakfast — *Exhibit Hall 4AB*	
7:00 AM – 7:45 AM	NSGC 2017 Board and Committee Leadership Orientation — *Room 307*	
8:00 AM – 8:30 AM	CEU **B02** Janus Series I: The *BAP1* Tumor Predisposition Syndrome — *Ballroom 6ABC*	
8:30 AM – 9:00 AM	Natalie Weissberger Paul National Achievement Award — *Ballroom 6ABC*	
8:30 AM – 4:00 PM	AEC Outreach Program — *Room 303*	
9:00 AM – 9:15 AM	CEU **B03** Beth Fine Kaplan Best Student Abstract Award — *Ballroom 6ABC*	
9:15 AM – 9:30 AM	CEU **B04** Best Full Member Abstract Award — *Ballroom 6ABC*	

9:30 AM – 10:15 AM	CEU **B05** NSGC State of the Society Address — *Ballroom 6ABC*				
10:15 AM – 10:30 AM	AEC Break — *Ballroom 6ABC Lobby*				
10:30 AM – 12:00 PM	CEU Educational Breakout Sessions				
	B06 Diagnosis and Treatment of Cystic Fibrosis: A (Not So) Simple Recessive Condition *Room 608 - 609*	**B07** Genetic Screening and Risk Assessments for Gamete Donors: The Need for Consensus Guidelines for Donor Eligibility *Room 606 - 607*	**B08** Historical Perspective of Hereditary Colon Cancer: A Personal and Professional Journey *Ballroom 6ABC*	**B09** Next Gen Teaching: The Lecture As We Know It Is Dead *Room 615 - 617*	**B10** The Results are In! Clinicians' Experience in Returning Results for Genomic Sequencing *Room 611 - 614*
12:00 PM – 1:00 PM	NSGC Committee Meetings				
	Access and Service Delivery Committee *Room 306*	AEC Subcommittee *Room 310*	Membership Committee * *Room 307* (*12:00 PM – 1:30 PM)		
12:30 PM – 1:30 PM	NSGC Committee Meetings				
	Education Committee *Room 308*	Practice Guidelines Committee *Room 303*	Marketing and Communications Workgroup *Room 602*	Public Policy Committee *Room 604*	
12:00 PM – 1:15 PM	CEU **B11** Improving Clinical Whole Exome Sequencing: The Impact of Shorter Turnaround Time, Atypical Findings, Re-analysis and Continued Research: — *Room 6E* **Sponsored by: Baylor Miraca Genetics Laboratories**				
1:30 PM – 3:00 PM	CEU Educational Breakout Sessions				
	B12 Assessment of Copy Number Variation Using Next Generation Sequencing Data *Room 615 - 617*	**B13** Patient Safety in the Era of Genomic Medicine: Implications for Genetic Counselors *Room 608 - 609*	**B14** Prenatal Diagnostic Exome Sequencing: Genomics for the Next Generation *Room 611 - 614*	**B15** Tier 1 Genomic Applications: Implementing Cancer Genomics via Public Health Programs *Ballroom 6ABC*	**B16** When Hoof Beats Mean Horses: New Insights into the Science and Personal Impact of Diagnosing and Treating Alzheimer's Disease *Room 606 - 607*
3:00 PM – 3:15 PM	AEC Break — *Ballroom 6ABC Lobby*				
3:15 PM – 4:15 PM	CEU **B17** Dr. Beverly Rollnick Memorial Lecture: So Much Yes: Creating Authentic Human Connection in Difficult Conversations — *Ballroom 6ABC*				
4:15 PM – 5:00 PM	NSGC Leadership Awards — *Ballroom 6ABC*				
5:00 PM – 5:30 PM	*Genome Magazine* Code Talker Awards Ceremony — *Ballroom 6ABC* **Presented by: *Genome Magazine*, Sponsored by: Invitae Corporation**				
5:00 PM – 7:45 PM	Exhibitor Suite Open — *Exhibit Hall 4AB*				
5:30 PM – 7:45 PM	AEC 35th Anniversary Reception — *Exhibit Hall 4AB* **Sponsored by: MNG Laboratories and Myriad Corporation**				
5:45 PM – 7:00 PM	CEU **B18** Posters with Authors, Group B Posters — *Exhibit Hall 4AB*				
7:00 PM – 8:15 PM	CEU **B19** Termination of Pregnancy for Indications of Genetic Disorder in Advanced Gestations — *Ballroom 6E* **Sponsored by: Boulder Abortion Clinic**				
7:00 PM	Various Program Reunions, see page 12 for more information				
7:30 PM – 8:30 PM	International SIG Meeting — *Room 310*				

Friday, September 30

7:00 AM – 7:00 PM	Registration Open — *Atrium Lobby*		
7:00 AM – 8:00 AM	AEC Breakfast — *Exhibit Hall 4AB*		
7:00 AM – 7:45 AM	CEU **C01** Key Challenges Associated with NGS-Based Tumor Profiling: Lab, Clinic and Patient Perspectives — *Ballroom 6E* **Sponsored by: Personalis, Inc.**		
7:00 AM – 7:45 AM	SIG Meetings		
	Education SIG — *Room 308*	Pediatric & Clinical SIG — *Room 307*	Research SIG — *Room 602*
7:00 AM – 7:45 AM	NSGC Past Board Member Breakfast — *Room 303*		
7:00 AM – 8:00 AM	Exhibitor Suite Open — *Exhibit Hall 4AB*		

SCHEDULE-AT-A-GLANCE

8:00 AM – 8:30 AM	CEU **C02** Janus Series II: Barth Syndrome: So Much More than Cardiomyopathy — *Ballroom 6ABC*			
8:30 AM – 9:30 AM	CEU **C03** Professional Issues Panel — *Ballroom 6ABC*			
9:30 AM – 9:45 AM	AEC Break — *Ballroom 6ABC Lobby*			
9:45 AM – 11:15 AM	CEU Concurrent Papers			
	C04 Access and Service Delivery *Room 606 - 607*	**C05** Genetic/Genomic Testing I *Room 611 - 614* **Sponsored by: Invitae Corporation**	**C06** Ethical, Legal and Social Issues *Room 615 - 617*	**C07** Counseling: Prenatal to Pediatrics *Room 608 - 609*
11:15 AM – 3:00 PM	Exhibitor Suite Open — *Exhibit Hall 4AB*			
11:30 AM – 12:45 PM	CEU **C08** Posters with Authors, Group C Posters — *Exhibit Hall 4AB*			
11:30 AM – 12:00 PM	NSGC SIG Chair Mixer — *Room 307*			
11:30 AM – 1:00 PM	Cancer SIG Meeting — *Room 604*			
12:45 PM – 2:00 PM	CEU **C09** Sequence in Seattle: Updates on Variant Classification and Prenatal WES — *Ballroom 6E* **Sponsored by: GeneDx**			
1:45 PM – 2:15 PM	American Board of Genetic Counseling (ABGC) Business Meeting — *Ballroom 6ABC*			
2:15 PM – 2:45 PM	Accreditation Council for Genetic Counseling (ACGC) Presentation — *Ballroom 6ABC*			
2:45 PM	Passport to Prizes Drawing — *Exhibit Hall 4AB*			
3:15 PM – 4:45 PM	CEU Educational Breakout Sessions			
	C10 Black & White…or Grey? Billing Integrity, Compliance and Legal Liability for the Genetic Counselor *Room 611 - 614*	**C11** Novel Precision Therapies for Genetic Disorders: Clinical Trials, Drug Development and the Perspectives of Genetic Counselors and our Patients *Room 606- 607*	**C12** Strategies for Affecting Behavior Change to Improve Clinical Outcomes in Genetic Testing *Room 615 - 616*	**C13** The Advent of Molecular Therapeutics for Duchenne and Becker Muscular Dystrophy and the Implications for Genetic Counselors *Room 608 - 609*	**C14** The Negative Genome Conundrum: What to Do When the Most Comprehensive Test is Negative *Ballroom 6ABC*
4:45 PM – 5:00 PM	AEC Break — *Ballroom 6ABC Lobby*			
5:00 PM – 5:45 PM	CEU **C15** – Genetic Counselors in Emerging Roles — *Ballroom 6ABC*			
5:45 PM – 6:00 PM	Audrey Heimler Special Project Award Presentation —*Ballroom 6ABC*			
6:00 PM – 6:30 PM	CEU **C16** – Jane Engelberg Memorial Fellowship Presentation — *Ballroom 6ABC*			
6:30 PM – 7:30 PM	SIG Meetings			
	Genomic Technologies SIG *Room 307*	Industry SIG *Room 602*	Personalized Medicine SIG *Room 303*	Public Health SIG *Room 308*
6:45 PM – 8:00 PM	**C17** Getting Down and Dirty with Ambry: The Truth About NGS — *Ballroom 6E* **Sponsored by Ambry Genetics**			
7:00 PM	Various Program Reunions, see page 12 for more information			

Saturday, October 1

7:00 AM – 8:00 AM	AEC Breakfast — *Ballroom 6ABC Lobby*
7:00 AM – 7:45 AM	CEU **D01** Genome-Wide cfDNA Testing: Has the Time Come? — *Ballroom 6E* **Sponsored by: Sequenom**
7:30 AM – 1:00 PM	Registration Open — *Atrium Lobby*
8:00 AM – 8:30 AM	CEU **D02** – Janus Series III: CHARGE: A Syndrome of Sensory Deficits and the Psychosocial Implications for Children and Families — *Ballroom 6ABC*
8:30 AM – 9:30 AM	CEU **D03** – Late-Breaking Plenary Session: The National Cancer Moonshot Initiative: A Significant Opportunity for Genetic Counselors — *Ballroom 6ABC*
9:30 AM – 10:00 AM	Incoming Presidential Address — *Ballroom 6ABC*
10:00 AM – 10:15 AM	AEC Break — *Ballroom 6ABC Lobby*

10:15 AM – 11:45 AM	CEU Educational Breakout Sessions				
	D04 Bioinformatics for Genetic Counselors 2.0: (More) Knowledge *Room 615 - 617*	**D05** Challenges of Prenatal Cell-free DNA Screening from the Patient Advocacy Perspective *Room 608 - 609*	**D06** Genetics and Primary Care: Preparing Primary Care Physicians for the Future of Genomic Medicine *Room 606 - 607*	**D07** It's Not You, It's Your Tumor: Navigating the Journey from Somatic Tumor Testing to the Genetics Clinic *Room 611 - 614*	**D08** Optimizing Compensation and Professional Advancement: From Negotiating Salary, Signing Bonuses and Benefits to Developing and/or Enhancing a Career Ladder *Room 618 - 620*
11:45 AM – 1:00 PM	Metabolism/LSD SIG Meeting — *Room 602*				
11:45 AM – 1:00 PM	CEU **D09** Hereditary Cancer Testing: Current and Future Challenges — *Ballroom 6E* **Sponosored by: Invitae Corporation**				
1:00 PM – 2:30 PM	CEU Concurrent Papers				
	D10 Building the Genetic Counseling Workforce *Room 615 - 617*	**D11** Genetic/Genomic Testing II *Room 611 - 614*	**D12** Adult Genetics *Room 608 - 609* **Sponsored by: Asuragen**	**D13** Counseling/ Psychological Issues *Room 606 - 607*	

Who will be named *Genome*'s Code Talker of the Year?

Genome Readers Honor Genetic Counselors Who Interpret Complexity With Compassion

Last April, *Genome* magazine kicked off an essay contest where patients and their families could pay tribute to a genetic counselor by nominating him or her for the **Code Talker Award**.

Come celebrate your profession by hearing stories written by people who've been touched by the skill and compassion of these three finalists! A book of essays will be made available at Invitae's reception later that evening. Don't miss it!

Amie Blanco, MS, LCGC
Nominated by Selena Martinez

Allison Goetsch, MS, CGC
Nominated by Melissa Bruebach

Anna Victorine, MS, CGC
Nominated by Brooke Johns

September 29th, 5:00 p.m. immediately following the NSGC's Leadership Awards

Sponsored by

INVITAE

Supported by

Genetic Alliance

Global Genes

NSGC INVITES YOU...

To celebrate all that we have accomplished as genetic counselors and as an organization over the past 35 years!

Join us at the **35th Anniversary Reception** on **Thursday, September 29** at 5:30 PM for drinks in the Exhibitor Suite
(Two drink tickets will be provided per attendee)

Reception sponsored by:

MNG LABORATORIES

myriad WHEN DECISIONS MATTER

BOULDER ABORTION CLINIC

Specializing in Late Abortion for Fetal Disorders
Quality Care for Women Since 1973

Warren M. Hern, MD, MPH, PhD

Director
American Board of Preventive Medicine
Fellow, American College of Preventive Medicine
Associate Clinical Professor, Department of Obstetrics & Gynecology
University of Colorado Health Sciences Center

Author
Abortion Practice
Philadelphia: J.B. Lippincott, 1984
Boulder: Alpenglo Graphics, 1990
(soft cover edition)

- Outpatient abortion over 30 menstrual weeks for selected patients with documented fetal anomaly, fetal demise, or medical indications
- Routine preoperative ultrasound evaluation for all patients
- Routine preoperative use of laminaria for maximum safety
- Individual counseling and support
- Highly experienced and dedicated professional staff
- Tradition of research and teaching in abortion services
- Founding institutional member, National Abortion Federation
- Bilingual staff and physician: fluent in Spanish, Portuguese, and Italian
- Recent research publications on request
- Consultations on request

1130 Alpine Avenue, Boulder, CO 80304
Tel: (303) 447-1361 • (800) 535-1287 • Fax: (303) 447-0020
www.drhern.com

REUNION INFORMATION

Please visit the NSGC AEC mobile app for updated reunion information

Time	Reunion Name	Location	Phone Number
Wednesday, September 28			
6:45 PM	University of Oklahoma Health Sciences Center	Tap House Grill 1506 Sixth Ave	206.816.3314
7:30 PM	University of Maryland - MGC Program	Tap House Grill 1506 Sixth Ave	206.816.3314
8:00 PM	Stanford University MS in Human Genetics and Genetic Counseling	Mr. West Cafe Bar 720 Olive Way	206.900.9378
8:00 PM	University of Cincinnati Genetic Counseling Program	Palomino Restaurant and Bar 1420 5th Ave	206.623.1300
8:00 PM	University of Texas at Houston	Local 360 Cafe & Bar 2234 1st Ave (at Bell St)	206.441.9360
8:00 PM	Wayne State University	Daily Grill, Pike Place Lobby 629 Pike Street	206.624.8400
8:30 PM	Canadian Genetic Counselling Programs: McGill University, University of British Columbia and University of Toronto	Tap House Grill 1506 Sixth Ave	206.816.3314
Thursday, September 29			
6:30 PM	University of Utah	TBD	
7:00 PM	Arcadia University Genetic Counseling Program	Orfeo 2107 3rd Ave	206.443.1972
7:00 PM	Case Western Reserve University	Elephant and Castle Pub 1415 5th Ave	206.624.9977
7:00 PM	Mount Sinai	Frolik Kitchen + Cocktails 1415 5th Ave	206.971.8015
7:00 PM	University of Alabama at Birmingham (UAB)	Blueacre Seafood 1700 7th Ave	206.659.0737
7:00 PM	The Joan H. Marks Graduate Program in Human Genetics, Sarah Lawrence College	The Triple Door 216 Union Street	206.838.4315
7:00 PM	University of Pittsburgh Genetic Counseling Training Program	Blueacre Seafood 1700 7th Ave	206.659.0737
7:00 PM	University of Wisconsin - Madison	TBD	
7:30 PM	JHU/NHGRI Counseling Program	Mayflower Park Hotel 405 Olive Way	206.623.8700
8:30 PM	California State University - Stanislaus and University of California Berkeley	TBD	
8:30 PM	University of Michigan	The Pike Brewing Company 1415 1st Ave	206.622.6044
8:30 PM	University of Minnesota Genetic Counseling Program	Tap House Grill 1506 Sixth Ave	206.816.3314
Friday, September 30			
7:00 PM	Northwestern University Graduate Program in Genetic Counseling	Tulio Ristorante Hotel Vintage-Seattle 1100 Fifth Ave	206.642.5500
8:00 PM	University of California, Irvine	TBD	
9:00 PM	Brandeis University	Blue Acre Seafood 1700 7th Ave	206.659.0737

CONVENTION CENTER FLOOR PLAN

Level 3



Level 4



Level 6



SESSION SPEAKERS AND OBJECTIVES

WEDNESDAY, SEPTEMBER 28

Pre-Conference Symposia

8:00 AM – 2:00 PM

A01 Double Dipping: Education Research in Diverse Settings

5.00 Contact Hours

1: Alix Darden, PhD, University of Oklahoma Health Sciences Center; 2: Carrie Guy, MS, CGC, Quest Diagnostics; 3: Claire Davis, MS, CGC, Sarah Lawrence College; 4: Erica Nelson, BS, 23andMe; 5: Emily Morris, MSc, CCGC, University of British Columbia

- Describe the principles and value of education research methodologies.
- Compare education research approaches and methods by example.
- Create education research questions through hands-on experience with mentors.
- Apply education research methodologies to designed research questions.

Submitted by: NSGC Education SIG and NSGC Research SIG

A02 Integrating Oncology and Genomics for Patient Care and Management

5.00 Contact Hours

1: Victoria Raymond, MS, LCGC, CCRP, Trovagene, Inc; 2: Mark Robson, MD, Memorial Sloan Kettering Cancer Center; 3: Joy Larsen Haidle, MS, CGC, Humphrey Cancer Center; 4: Stephen B. Gruber, MD, PhD, MPH, USC Norris Comprehensive Cancer Center; 5: Thomas Slavin, MD, FACMG, DABMD, City of Hope Cancer Center; 6: Sara Pirzadeh Miller, MS, CGC, UT Southwestern Medical Center; 7: Tom Walsh, PhD, University of Washington

- Discuss somatic tumor testing clinical decision making.
- Describe how the information we provide to oncologists is utilized.
- Recognize the next frontier of genomic research.

Submitted and Sponsored by: NSGC Familial Cancer SIG

A03 Oh the Places You'll Go! Genetic Counseling as a Fast Pass to Personal and Professional Growth

5.00 Contact Hours

1: Kimberly Banks, MS, CGC, MBA, Guardant Health; 2: Elizabeth Butler, MS, CGC, GeneDx; 3: Melissa Maisenbacher, MS, CGC, Natera; 4: Donna McDonald-McGinn, MS, LCGC, The Perelman School of Medicine of the University of Pennsylvania, The Children's Hospital of Philadelphia; 5: Matt Tschirgi, MS, LCGC, Progenity; 6: Kathleen Valverde, MS, CGC, Arcadia University; 7: Leah Williams, MS, CGC, GeneDx

- Distinguish professional development from career advancement.
- Describe various strategies and paths of professional development as a genetic counselor.
- Generate a set of professional skills to place a genetic counselor on a path of career advancement.
- Examine characteristics of CVs and cover letters of genetic counseling applicants in a critical manner.

A04 Opening the cfDNA Non-invasive Prenatal Screen Floodgates: Expansion into the General Population and Its Impact on Industry Counselors, Clinical Providers and Policy Makers

5.00 Contact Hours

1: Mary Norton, MD, University of California, San Francisco; 2: Erica Sturm, MS, CGC, Perinatal Quality Foundation; 3: Megan Maxwell, MS, LGC, Quest Diagnostics; 4: Lisa Demers, MS, CGC, Roche Diagnostics; 5: Colleen Wu, MS, CGC, Evicore Healthcare; 6: Kelly Chen, MS, CGC, LGC, Personalis, Inc.; 7: Danielle LaGrave, MS, LCGC, ARUP Laboratories; 8: Edye Conway, MS, CGC, Saint Alphonsus Maternal Fetal Medicine; 9: Shannon Mulligan, MS, CGC, Baylor College of Medicine, Texas Children's Fetal Center; 10: Kelly L. Adams, MS, LCGC, Kaiser Permanente

- Assess the unique factors in cfDNA non-invasive prenatal screening that impact pre- and post-test patient counseling for the general population.
- Identify challenges and strategies related to expanding pre-test education for cfDNA non-invasive prenatal screening to any woman in pregnancy.
- Describe factors that impact insurance coverage and reimbursement for cfDNA non-invasive prenatal screening, including analytical validity, clinical validity and clinical utility.
- Explore complex cases from both laboratory and clinical perspectives.

Submitted and Sponsored by: NSGC Prenatal SIG

A05 Religion and Spirituality in Genetic Counseling

5.00 Contact Hours

1: Kate Wilson, MS, CGC, Quest Diagnostics; 2: Katelynn Sagaser, MS, CGC, Johns Hopkins Hospital, Prenatal Diagnosis and Treatment Center; 3: Jennifer Lemons, CGC, UT Health Science Center at Houston; 4: Brent Peery, DMin, BCC, Memorial Hermann–Texas Medical Center

- Define religiosity and spirituality (R/S) as well as several different belief systems.
- Illustrate possible R/S complexities that may arise in healthcare, specifically in regard to genetic counseling.
- Evaluate when R/S exploration would be beneficial in a genetic counseling session.
- Identify considerations and perceived challenges of genetic counselors related to performing R/S assessment.

Submitted by: NSGC Membership Committee

A06 The Genetic Testing Laboratory: Insider View for Genetic Counselors

5.00 Contact Hours

1: Katrina Kotzer, MS, CGC, Mayo Clinic; 2: Patricia Winters, MS, CGC, Illumina, Inc.; 3: Mathew Bower, MS, CGC, University of Minnesota Health; 4: W. Andrew Faucett, MS, LGC, Geisinger; 5: Heather MacLeod, MS, CGC, Cardiovascular Genetics Consultant; 6: Danielle LaGrave, MS, LCGC, ARUP Laboratories; 7: Jill Rosenfeld Mokry, MS, CGC, Baylor College of Medicine; 8: Alice Tanner, PhD, MS, CGC, FACMG, Emory University, Emory Genetics Laboratory, LLC; 9: Michelle Dolan, MD, University of Minnesota; 10: Lisa Sniderman King, MSc, CGC, University of Washington

- Describe in-depth specifics of genetic testing terminology and technologies relevant to both clinical practice and the practice of laboratory genetic counseling.
- Analyze largely unknown aspects of the genetic testing laboratory, including the history and importance of regulatory bodies, the test development process, the laboratory infrastructure and laboratory business relationships.
- Evaluate nuances and challenges within the genetic testing laboratory through the evaluation of ethical case examples and contributions to research.

Submitted and Sponsored by: NSGC Industry SIG

SESSION SPEAKERS AND OBJECTIVES

Plenary Sessions

3:45 PM – 4:45 PM

A07 Population-Based Screening for Inherited Predisposition to Breast and Ovarian Cancer

1.00 Contact Hour

1: Mary-Claire King, PhD, University of Washington; 2: Muin J. Khoury, MD, PhD, Centers for Disease Control and Prevention; 3: Joy Larsen Haidle, MS, CGC, Humphrey Cancer Center; 4: Jean Enersen, King 5 TV

- Describe expert opinions about population screening for Hereditary Breast and Ovarian Cancer Syndrome (HBOC).
- Appraise potential benefits as well as barriers to population-based screening for HBOC.
- Consider critical elements of a proposed screening program including the population served, tests included, variants reported and follow-up care.

4:45 PM – 5:45 PM

A08 Gene to Community, Community to Action: The Power of Social Media in Genomics

1.00 Contact Hour

1: Matthew Might, PhD, University of Utah

- Describe non-traditional methods to create and foster connection of patients with rare diseases.
- Explain how genetic counselors can connect with patient-driven efforts to facilitate sharing of research data, patient advocacy and community-building.

THURSDAY, SEPTEMBER 29

Sponsored Breakfast Session

7:00 AM – 7:45 AM

B01 Integrated Genetics: Reproductive Genetics and Hereditary Cancer Screening – A Legal Perspective

0.50 Contact Hour

1: Phillip J. Duffy, Esq. Gibbons, P.C

- Describe concepts that participants can utilize to avoid and manage legal risk in their daily practice.
- Explain the legal importance of defining policies and procedures based on professional guidelines, providing informed consent and maintaining documentation.

Sponsored by: Integrated Genetics

Janus Series

8:00 AM – 8:30 AM

B02 The *BAP1* Tumor Predisposition Syndrome

0.50 Contact Hour

1: Robert Pilarski, MS, LGC, MSW, The Ohio State University

- Review the hereditary basis of uveal melanoma and the contribution of *BAP1* mutations.
- Summarize the signs of the *BAP1* tumor predisposition syndrome (BTPS) and the spectrum of associated cancers, penetrance estimates and management recommendations.
- Discuss the potential role of research studies for patients and families suspected of having BTPS.

Best Abstract Awards

9:00 AM – 9:30 AM

Beth Fine Kaplan Best Student Abstract Award

B03 Genetic Counseling Increases Parental Knowledge and Psychological Adaptation to Turner Syndrome Diagnosis

0.25 Contact Hour

1: Caitlin A. Austin

- Describe the effects of genetic counseling on adaptation in parents of children with Turner Syndrome.

Best Full Member Abstract Award

B04 Adapting Evidence-Based Strategies for Effective Communication in Cancer Genetic Counseling

0.25 Contact Hour

1: Robin Lee, MS, CGC

- Describe evidence-based strategies for effective communication with patients of limited health literacy.

Plenary Session

9:30 AM – 10:15 AM

B05 NSGC State of the Society Address

0.75 Contact Hour

1: Jehannine Austin, MSc, PhD, CGC, CCGC, President, National Society of Genetic Counselors

- Describe the activities of NSGC over the past year as related to the advancement of the profession of genetic counseling.
- Assess NSGC's advocacy efforts over the course of 2016.
- Outline the strategic initiatives in NSGC's 2016 – 2018 strategic plan.

Educational Breakout Sessions

10:30 AM– 12:00 PM

B06 Diagnosis and Treatment of Cystic Fibrosis: A (Not So) Simple Recessive Condition

1.50 Contact Hours

1: Elinor Langfelder-Schwind, MS, CGC, Mount Sinai Beth Israel; 2: Matthew Pastore, MS, LGC, Nationwide Children's Hospital; 3: Laura Fischer, MS, CGC, Women and Children's Hospital of Buffalo; 4: Lisa Green, MA, Happy Heart Families; 5: Bonnie Watts Ramsey, MD, Seattle Children's Research Institute

- Describe recent developments in the field of cystic fibrosis (CF) research and mutation-specific therapies.
- Explain common CF newborn screening algorithms and their potential diagnostic outcomes.
- Recognize the needs of the family through the diagnostic and treatment journey (family perspective).
- Compare benefits and limitations of various CF testing platforms for risk assessment.

Submitted by: NSGC Cystic Fibrosis SIG

SESSION SPEAKERS AND OBJECTIVES

B07 Genetic Screening and Risk Assessments for Gamete Donors: The Need for Consensus Guidelines for Donor Eligibility

1.50 Contact Hours

1: Lauren J. Isley, MS, LCGC, Counsyl, Inc.; 2: Amy Vance, MS, LCGC, Bay Area Genetic Counseling; 3: Peggy Orlin, MS, MFT, Private Practice at Pacific Fertility Center; 4: Lauri Black, MS, LCGC, Pacific Reproductive Genetic Counseling

- Summarize the current regulations and guidelines for gamete donor screening.
- Describe existing gamete donor screening practices, including carrier testing, psychological assessment and family medical history screening.
- Outline the issues behind the lack of uniform donor screening processes between egg and sperm donors and across gamete donor facilities.
- Assess the impact of the lack of uniform processes when performing a risk assessment and providing patient care.
- Review the efforts to establish consensus eligibility guidelines for gamete donors.

Submitted and Sponsored by: NSGC ART/Infertility SIG

B08 Historical Perspective of Hereditary Colon Cancer: A Personal and Professional Journey

1.50 Contact Hours

1: Richard Boland, MD; 2: Heather Hampel, MS, LGC, The Ohio State University; 5. Linda Robinson, MS, CGC, UT Southwestern Medical Center

- Describe the transformation of genetic testing for hereditary colon cancer over the last 40 years.
- Discuss the epigenetic factors for hereditary colon cancer and the implication on risk reduction.
- Describe the personal impact of hereditary cancer on a family.
- Discuss the international impact of population-based screening for Lynch syndrome.

B09 Next Gen Teaching: The Lecture As We Know It Is Dead

1.50 Contact Hours

1: Beverly M. Yashar, MS, PhD, CGC, University of Michigan; 2: Emily Edelman, MS, CGC, The Jackson Laboratory; 3: Catherine Reiser, MS, CGC, University of Wisconsin–Madison; 4: MaryAnn W. Campion, EdD, MS, CGC, Stanford University School of Medicine; 5: Leslie Cohen, MS, PhD, Case Western Reserve University School of Medicine

- Describe emerging educational and assessment methods.
- Discuss how to adapt these innovative approaches to diverse groups of learners.
- Apply active learning concepts to develop a mock genetic educational program including teaching and assessment methods.

Submitted by: NSGC Education SIG

B10 The Results are In! Clinicians' Experience in Returning Results for Genomic Sequencing

1.50 Contact Hours

1: Sarah Scollon, MS, CGC, Baylor College of Medicine, Texas Children's Hospital; 2: Julia Wynn, MS, CGC, New York Presbyterian Columbia; 3: Katie Lewis, ScM, CGC, National Institutes of Health

- Identify how return of results for whole exome sequencing/whole genome sequencing (WES/WGS) differs from single gene or panel genetic testing and how that may alter the return of results process.
- Recognize common challenges faced in the return of results process and methods for addressing these challenges.
- Apply lessons learned from the Clinical Sequencing Exploratory Research clinicians to your own return of results process in order to increase efficiency and improve patient experiences at your home institution.
- Recognize the valuable role of the genetic counselor in various areas of the WES/WGS return of results process.

Sponsored Lunch Session

12:00 PM – 1:15 PM

B11 Improving Clinical Whole Exome Sequencing: The Impact of Shorter Turnaround Time, Atypical Findings, Re-analysis and Continued Research

1.00 Contact Hour

1: Alicia Braxton, MS, CGC, Baylor College of Medicine; 2: Yaping Yang, PhD, FACMGG, Baylor College of Medicine; 3: Pengfei Liu, PhD, FACMGG, Baylor College of Medicine; 4: Seema Lalani, MD, Baylor College of Medicine

- Illustrate categories of genetic variation that can be detected through whole exome sequencing (WES) testing.
- Summarize the WES testing process to optimize turnaround time and increase detection rate.
- State how WES re-analysis increases detection rate for initially negative cases.
- Indicate research opportunities available for patients with negative clinical exome.
- Examine clinical phenotypes in relationship to each other as a new disease cohort.

Sponsored by: Baylor Miraca Genetics Laboratories

Educational Breakout Sessions

1:30 PM – 3:00 PM

B12 Assessment of Copy Number Variation Using Next Generation Sequencing Data

1.50 Contact Hours

1: Kimberly Banks, MS, CGC, MBA, Guardant Health; 2: Kelly D.F. Hagman, MS, CGC, Ambry Genetics; 3: Dale Muzzey, PhD, Counsyl, Inc; 4: Zhongming Zhao, PhD, UT Health Science Center at Houston; 5: Hsiao-Mei Lu, PhD, Ambry Genetics

- Recall data regarding the use of next-generation sequencing (NGS) data for copy number variation (CNV) detection.
- Recognize the current use of CNV analysis from NGS in clinical practice.
- Interpret clinical reports describing results from CNV analysis from NGS data.

Submitted and Sponsored by: NSGC Genomic Technologies SIG

B13 Patient Safety in the Era of Genomic Medicine: Implications for Genetic Counselors

1.50 Contact Hours

1: Wendy R. Uhlmann, MS, CGC, University of Michigan; 2: Thomas H. Gallagher, MD, University of Washington; 3: Stephanie M. Fullerton, DPhil, University of Washington

- Review basic principles of patient safety.
- Identify potential errors that have been reported to arise in the order, analysis, interpretation and follow-up of genetic tests.
- Recognize the implications of genetic testing for patient safety.
- Identify strategies for addressing and enhancing patient safety in your own genetic counseling practice.

ONE SIZE DOES NOT FIT ALL

Order testing your way with our new custom panel options.

Stop by Booth #316

Ambry Genetics®

SESSION SPEAKERS AND OBJECTIVES

B14 Prenatal Diagnostic Exome Sequencing: Genomics for the Next Generation

1.50 Contact Hours

1: Christina Alamillo, MS, CGC, LGC, Ambry Genetics; 2: Alicia Braxton, MS, CGC, Baylor Miraca Laboratories, Baylor College of Medicine; 3: Catherine Burson, MS, CGB, Center for Maternal Fetal Health at Rocky Mountain Hospital for Children; 4: Lauren Westerfield, MS, CGC, Baylor College of Medicine, Texas Children's Hospital; 5: Curtis R. Coughlin II, MS, MBe, CGC, University of Colorado School of Medicine

- Discuss the clinical utility of diagnostic exome sequencing in the prenatal population, including use for diagnosis, decision-making, preparation, family planning and pregnancy, and birth management.
- Describe the findings of the published literature regarding prenatal diagnostic exome sequencing.
- Identify ethical, legal and social implications of prenatal diagnostic exome sequencing.

Submitted and Sponsored by: NSGC Prenatal SIG

B15 Tier 1 Genomic Applications: Implementing Cancer Genomics via Public Health Programs

1.50 Contact Hours

1: Muin J. Khoury, MD, PhD, Centers for Disease Control and Prevention, CDC; 2: Debra Duquette, MS, CGC, Michigan Department of Community Health; 3: Natasha F. Bonhomme, Genetic Alliance

- Summarize the Centers for Disease Control and Prevention (CDC) Tier 1 Genomic Applications and their relevance to public health practice.
- Describe the Tier 1 implementation methods for public health departments that are outlined in the CDC Tier 1 Genomic Applications Toolkit, including bi-directional cancer registry reporting, educational programs, developing and tracking surveillance indicators, informing policy making and cascade screening.
- Identify successful examples of state public health programs and patient advocacy work involving Tier 1 Genomic Applications.
- Identify patient advocacy work being done to increase awareness of Tier 1 Genomic Applications.

Submitted by: NSGC Public Health SIG

B16 When Hoof Beats Mean Horses: New Insights into the Science and Personal Impact of Diagnosing and Treating Alzheimer's Disease

1.50 Contact Hours

1: Zachary Miller, MD, University of California, San Francisco; 2: Jill S. Goldman, MS, MPhil, CGC, Columbia University Medical Center; 3: Jamie Tyrone, RN, B.A.B.E.S. (Beating Alzheimer's by Embracing Science); 4: Susan Hahn, MS, CGC, Quest Diagnostics

- Recognize red flags for familial/ hereditary risk for Alzheimer's disease and other dementia.
- Describe current practices regarding genetic testing, imaging and biomarkers in predicting, diagnosing and treating dementia.
- Discuss the personal, logistical and emotional impact of undergoing comprehensive risk assessment for dementia.
- Explain how current and future drug studies may be beneficial to families with hereditary dementias.

Submitted and Sponsored by: NSGC Neurogenetics SIG

Dr. Beverly Rollnick Memorial Lecture

3:15 PM – 4:15 PM

B17 So Much Yes: Creating Authentic Human Connection in Difficult Conversations

1.00 Contact Hour

1: Belinda Fu, MD, Mayutica Institute for Communication in Medicine, University of Washington School of Medicine, Swedish Medical Center

- Experience how the act of affirmation can forge sincere connections and minimize misunderstanding.
- Heighten awareness of verbal and non-verbal behaviors that affect communication.
- Explore how improvisational theater skills can improve communication in medicine.

Sponsored by: Dr. Beverly Rollnick Memorial Fund

Sponsored Dinner Session

7:00 PM – 8:15 PM

B19 Termination of Pregnancy for Indications of Genetic Disorder in Advanced Gestations

1.00 Contact Hour

1: Warren M. Hern, MD, MPH, PhD, Boulder Abortion Clinic

- Describe the relevance of these services to genetic counseling.
- Identify the purpose, basic principles, and components of clinical practice including grief support.
- Outline the basic operative procedures and clinical results of this care.

Sponsored by: Boulder Abortion Clinic

FRIDAY, SEPTEMBER 30

Sponsored Breakfast Session

7:00 AM – 7:45 AM

C01 Key Challenges Associated with NGS-Based Tumor Profiling: Lab, Clinic and Patient Perspectives

0.50 Contact Hour

1: Heather Wetzel, MS, LCGC, Personalis, Inc.; 2: Erin Ayash, MS, LCGC, Personalis Inc.; 3: Luna Okada, MS, CGC, AMITA Health Saint Alexius Medical Center

- Define the conditions and logistical considerations for somatic tumor testing.
- Summarize what the results of somatic tumor testing mean for your patients.
- Examine some of the challenges associated with somatic tumor testing including the significance and ethical considerations regarding pathogenic germline variants.
- Evaluate the experience of tumor profiling from a patient's perspective.

Sponsored by: Personalis, Inc.

SESSION SPEAKERS AND OBJECTIVES

Janus Series
8:00 AM – 8:30 AM

C02 Barth Syndrome: So Much More than Cardiomyopathy
0.50 Contact Hour

1: Rebecca McClellan, MGC, CGC, Johns Hopkins School of Medicine

- Review the multisystem clinical presentation and discuss what we know about the disorder's connection to cardiolipin remodeling.
- Explore the varied experiences and often conflicting roles of a genetic counselor working with a rare disease support group.
- Outline the challenges faced by X-linked disease carriers.

Submitted by: NSGC Cardiovascular SIG

Plenary Session
8:30 AM – 9:30 AM

C03 Professional Issues Panel
1.00 Contact Hour

1: Jennifer Hoskovec, MS, CGC, University of Texas Medical School at Houston, 2: John Richardson, NSGC, 3: Cathy Wicklund, MS, CGC, Northwestern University Feinberg School of Medicine

- Review current initiatives focused on assessing demand for genetic counselors over the next 10 years.
- Outline strategies being pursued by ABGC, ACGC, AGCPD and NSGC to support expansion of the genetic counselor workforce to meet the future demand for genetic services.
- Review the status of federal legislation to add genetic counselors as authorized providers under Medicare.
- Outline NSGC member involvement in supporting the pending bill.

Sponsored Lunch Session
12:45 PM – 2:00 PM

C09 Sequence in Seattle: Updates on Variant Classification and Prenatal WES
1.00 Contact Hour

1: Elizabeth Butler, MS, CGC, GeneDx; 2: Carin Yates, MS, CGC, GeneDx; 3: Michelle Cahr, MS, CGC; Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine

- Explain variant classification methods and procedures.
- Examine the reasons for variant reclassification and its impact on clinical care.
- Describe the clinical utility of whole exome sequencing (WES) in the prenatal setting.
- Discuss the current knowledge of WES in the reproductive setting.

Sponsored by: GeneDx

Educational Breakout Sessions
3:15 PM – 4:45 PM

C10 Black & White…or Grey? Billing Integrity, Compliance and Legal Liability for the Genetic Counselor
1.50 Contact Hours

1: Jodie Vento, MS, CGC, Children's Hospital of Pittsburgh of UPMC; 2: S. Craig Holden, Ober\|Kaler; 3: Gillian Hooker, PhD, ScM, CGC, NextGxDx

- Describe the federal anti-kickback, Stark, and other billing compliance regulations, and their roles in genetic testing services.
- Discuss the role of the clinical genetic counselor in regards to billing practice compliance and "genesurance" counseling.
- Recognize red flags indicating that billing practices may be out of compliance.

Submitted by: NSGC Access and Service Delivery Committee

C11 Novel Precision Therapies for Genetic Disorders: Clinical Trials, Drug Development and the Perspectives of Genetic Counselors and Patients
1.50 Contact Hours

1: Christian Jacobs, The FH Foundation; 2: Julie C. Sapp, ScM, CGC, National Human Genome Research Institute, National Institutes of Health; 3: Leslie Leinwand, PhD, University of Colorado Boulder; 4: Haroon Hashmi, PhD, Alnylam Pharmaceuticals

- Discuss the value of and considerations for patient participation in clinical trials.
- Identify ways that genetic information can drive therapeutic development.
- Explain the pathway for drug development.

Submitted by: NSGC Personalized Medicine SIG, NSGC Research SIG and NSGC Cardiovascular Genetics SIG

Sponsored by: NSGC Cardiovascular Genetics SIG

C12 Strategies for Affecting Behavior Change to Improve Clinical Outcomes in Genetic Counseling
1.50 Contact Hours

1: Scott T. Walters, PhD, University of North Texas Health Science Center

- Recall key components and principles of motivational interviewing (MI) in addressing risk behaviors.
- Describe client "change talk" and how it contributes to MI practice.
- Review MI techniques, including responding to client resistance, eliciting and reinforcing "change talk" and consolidating commitment around change.

C13 The Advent of Molecular Therapeutics for Duchenne and Becker Muscular Dystrophy and the Implications for Genetic Counselors
1.50 Contact Hours

1: Lauren Morgenroth, MS, CGC, Childrens' National Health System; 2: Ann Lucas, MS, CGC, Parent Project Muscular Dystrophy; 3: Ann Martin, MS, CGC, Parent Project Muscular Dystrophy; 4: Laurie Paschal

- Describe the current natural history of Duchenne and Becker muscular dystrophy (DBMD).
- Explain the different therapeutic strategies in the pipeline for DBMD, with an emphasis on molecular therapeutics.
- Discuss the importance of rare disease patient registries such as DuchenneConnect.
- Recognize the benefits and risks that families face when participating in research.

Submitted by: NSGC Neurogenetics SIG

C14 The Negative Genome Conundrum: What To Do When the Most Comprehensive Genetic Test is Negative
1.50 Contact Hours

1: Michael O. Dorschner, PhD, University of Washington; 2: Allison L. Cirino, MS, CGC, Brigham and Women's Hospital; 3: Laura Amendola, MS, CGC, University of Washington; 4: Sarah Scollon, MS, CGC, Baylor Texas Children's Hospital; 5: Julia Wynn, MS, CGC, Columbia University Medical Center; 6: Sawona Biswas, MS, CGC, Children's Hospital of Philadelphia

- Recognize the technical limitations of whole exome sequencing/genome sequencing (WES/WGS) with a focus on current sequencing methods, interpretation of variants and variant databases.
- Discuss common issues raised in disclosing and managing negative WES/WGS results.
- Examine approaches to counseling patients about the limitations of WES/WGS, setting realistic expectations and disclosing negative results.

Submitted and Sponsored by: Genomic Technology SIG

SESSION SPEAKERS AND OBJECTIVES

Plenary Sessions

5:00 PM – 5:45 PM

C15 Genetic Counselors in Emerging Roles

0.50 Contact Hour

1: Steven Keiles, MS, LCGC, Quest Diagnostics; 2: Heather L. Shappell, MS, CGC, Beacon Laboratory Benefit Solutions, Inc.; 3: Angela Walter, MS, CGC, Sanofi Genzyme Corporation; 4: Joan Scott, MS, CGC, Maternal and Child Health Bureau, Health Resource and Services Administration

- Highlight three emerging roles for genetic counselors in different aspects of the health system.
- Compare the professional pathways of genetic counselors who have taken unique roles and outline the skills and resources helped them along the way.
- Evaluate the value genetic counselors can bring to emerging roles in healthcare.

Submitted by: NSGC Roles of Genetic Counselors Taskforce

6:00 PM – 6:30 PM

C16 Jane Engelberg Memorial Fellowship (JEMF) Presentation

0.50 Contact Hour

1. Leslie Evans, MS, CGC, Chair, JEMF Advisory Group; 2. Cynthia A. James, ScM, PhD, CGC, 2015 JEMF Awardee

- Review the history of the JEMF award and provide an update on current initiatives.
- Illustrate the utility of a psychological model for planning a research study and executing data analysis.
- Evaluate evidence of the influence of family history, genetic test results, demographic and clinical factors. on adaptation to living with or at risk for arrhythmogenic right ventricular cardiomyopathy.

Sponsored Dinner Session

6:45 PM – 8:00 PM

C17 Getting Down and Dirty with Ambry: The Truth About NGS

1: Aaron Elliott, PhD, Ambry Genetics; 2: Laura Panos-Smith, MS, CGC, Ambry Genetics

Sponsored by: Ambry Genetics

SATURDAY, OCTOBER 1

Sponsored Breakfast Session

7:00 AM – 7:45 AM

D01 Genome-wide cfDNA Testing: Has the Time Come?

0.50 Contact Hour

1: Erica Soster, MS, CGC, Sequenom; 2: Tom Westover, MD, Cooper University Hospital

- Summarize initial experiences with genome-wide cfDNA testing in the first year of use from a clinical laboratory perspective.
- Examine the implementation and utility of genome-wide cfDNA testing from a clinician's perspective.

Sponsored by: Sequenom

Janus Series

8:00 AM – 8:30 AM

D02 CHARGE: A Syndrome of Sensory Deficits and the Psychosocial Implications for Children and Families

0.50 Contact Hour

1: Meg Hefner, MS, CGC, Saint Louis University School of Medicine

- Define the diagnostic criteria and testing options for CHARGE syndrome in a clinical setting.
- Recognize how hearing loss, vision loss and other sensory deficits alter typical infant development and affect the clinical and psychosocial needs of patients with CHARGE syndrome and their family members.
- Explain the impact and implications of deaf-blind educational programs for patients diagnosed with CHARGE syndrome.

Late Breaking Plenary Session

8:30 AM – 9:30 AM

D03 The National Cancer Moonshot Initiative: A Significant Opportunity for Genetic Counselors

1.00 Contact Hour

1. L. Michelle Bennett, PhD, National Cancer Institute NIH, DHHS

- Summarize the goals of the National Cancer Moonshot Initiative.
- List the findings and recommendations of the Blue Ribbon Panel (BRP).
- Identify opportunities for genetic counselor involvement in the Cancer Moonshot Initiative in the context of the BRP report.

Educational Breakout Sessions

10:15 AM – 11:45 AM

D04 Bioinformatics for Genetic Counselors 2.0: (More) Knowledge is Power

1.50 Contact Hours

1: Michelle Fox, MS, LCGC; 2: Erica Ramos, MS, LCGC, Illumina, Inc.; 3: Eric W. Klee, PhD, Mayo Clinic; 4: Stephen E. Lincoln, Invitae

- Describe bioinformatics tools and databases used in clinical testing, in particular for quality assessment, variant annotation and classification.
- Contrast differing uses of bioinformatics databases and tools by various genetic tests.
- Discuss bioinformatics issues with laboratories, non-genetics clinicians and patients.
- Identify ongoing developments in bioinformatics that will impact clinical practice in the future.

Submitted and Sponsored by: NSGC Industry SIG

D05 Challenges of Prenatal Cell-free DNA Screening from the Patient Advocacy Perspective

1.50 Contact Hours

1: Cori Feist, CGC, Oregon Health and Science University; 2: Stephanie Meredith, MA, University of Kentucky Human Development Institute; 3: Megan Allyse, PhD, Mayo Clinic; 4: Victoria Miller, Trisomy 18 Foundation; 5: Myra Byrd, AXYS; 6: Marsha Michie, PhD, University of California San Francisco; 7: Linzee Carroll, 11q Research and Resource Group

- Provide examples of the impact of cfDNA screening on non-profit patient advocacy groups.
- Review evidence-based research identifying the most common challenges for patient advocacy groups.
- Develop strategies for support of these groups by the genetic counseling community.

SESSION SPEAKERS AND OBJECTIVES

D06 Genetics and Primary Care: Preparing Primary Care Physicians for the Future of Genomic Medicine

1.50 Contact Hours

1: Jason Vassy, MD, MPH, SM, Brigham and Women's Hospital, Harvard Medical School; 2: Carrie Lynn Blout, MS, CGC, LGC, Brigham and Women's Hospital; 3: Michael Dougherty, PhD, American Society of Human Genetics

- Describe the current landscape of primary care physicians and their comfort with genomic medicine.
- Explore outcomes surrounding the integration of whole genome sequencing into primary care and the provision of genetic counseling by primary care physicians.
- Discuss opportunities to facilitate the integration of genomics into primary care practice.

Submitted by: NSGC Personalized Medicine SIG

D07 It's Not You, It's Your Tumor: Navigating the Journey from Somatic Tumor Testing to the Genetics Clinic

1.50 Contact Hours

1: Jennifer Morrissette, PhD, Center for Personalized Diagnostics, University of Pennsylvania; 2: Dana Farengo Clark, MS, CGC, University of Pennsylvania; 3: Daniel Catenacci, MD, University of Chicago; 4: Jacquelyn Powers, MS, LCGC, University of Pennsylvania

- Examine the current landscape of next generation sequencing (NGS) tumor testing to help genetic counselors identify somatic variants that may be more suggestive of a germline finding.
- Review implementation and early outcomes of University of Pennsylvania's patient referral process for somatic findings warranting genetic counseling and/or germline mutation testing.
- Review the University of Chicago's framework in development for pre- and post-test informed consent and counseling for patients undergoing NGS tumor testing based upon experience gained by retrospective review and stratification of GI clinical cohort.
- Discuss case examples for when to proceed with clinical germline genetic testing for a somatic finding.

D08 Optimizing Compensation and Professional Advancement: From Negotiating Salary, Signing Bonuses and Benefits to Developing and/or Enhancing a Career Ladder

1.50 Contact Hours

1: Angela Trepanier, MS, CGC, Wayne State University; 2: Steven Keiles, MS, LCGC, Quest Diagnostics; 3: Shannon Morill-Cornelius, MS, LCGC, Western Connecticut Health Network; 4: Catherine Reiser, MS, CGC, University of Wisconsin; 5: Kristen Shannon, MS, LGC, Massachusetts General Hospital; 6: Katherine Wusik Healy, LGC, Cincinnati Children's Hospital Medical Center

- Recognize the opportunity that the current job market presents in terms of negotiating for better compensation and benefits and/or seeking advancement opportunities.
- Summarize strategies for negotiating for increased salary and benefits.
- Describe career ladders as a means of delineating advancement opportunities.
- Recognize the process of implementing and modifying a career ladder.
- Communicate a plan for achieving one's own compensation and/or advancement goals.

Sponsored Lunch Session

11:45 AM – 1:00 PM

D09 Hereditary Cancer Testing: Current and Future Challenges

1.00 Contact Hour

1: Andrea Forman, MS, LCGC, Fox Chase Cancer Center; 2. Steve Lincoln, Invitae Corporation; 3. Julie Cohen, ScM, Kennedy Krieger Institute

- Assess current challenges clinical genetic counselors face in terms of test selection, patient volume and clinical management.
- Discuss appropriate questions to ask when comparing and selecting genetic testing laboratory partners.
- Assess the emerging challenges and opportunities for genetic counselors in clinical practice.

Sponosored by: Invitae Corporation

CONCURRENT PAPERS

Friday, September 30

1.50 Contact Hours

	C04: Access and Service Delivery • Explore novel approaches to improve genetic counseling service delivery. • Illustrate how to use electronic tools to deliver genetics-focused education. • Discuss varied approaches to providing genetic counseling.	**C05:** Genetic/Genomic Testing I • Explore unique challenges in providing cancer focused care. • Analyze the impact of cancer genetic/genomic testing on patients and clinicians. • Develop tools to address variables in cancer genetic/genomic testing. Sponsored by: INVITAE	**C06:** Ethical, Legal and Social Issues • Identify unique ramifications of genetic testing for prenatal/pediatric populations. • Discuss the clinical uses of social media tools by genetic counselors. • Construct perspectives on the use of self-disclosure.	**C07:** Counseling: Prenatal to Pediatrics • Explore unique challenges in providing genetic/genomic testing to prenatal and pediatric populations. • Summarize the prenatal counseling milieu. • Identify novel ways of addressing patients' clinical/emotional needs.
	Room 606 - 607	**Room 611 - 614**	**Room 615 - 617**	**Room 608 - 609**
9:45 AM - 10:00 AM	Finding the Right Mix: Optimizing the Utilization of the Genetic Counseling Skill Set *P. Read*	We Can Work It Out: Hereditary Cancer Test Utilization Management in a Large Commercial Laboratory *L. Cheng*	Ramifications of Excessive Autosomal Homozygosity Detected by Single Nucleotide Polymorphism (SNP) Array: Investigation of Incestuous versus Non-Incestuous Relationships *J. Chen*	Comparing Data from POC Testing of First, Second and Third Trimester Pregnancy Losses Highlights Differences and the Need for Genetic Counseling Outside the Box *K. Howard*
10:00 AM - 10:15 AM	A Novel Approach to Lab-based Clinical Genetic Counseling *K. Lynch*	Does the Mutation Fit the Family? Incidental Findings from Cancer Gene Panel Testing *N. Brown*	Melanoma Risk Genetic Counseling in Children: Engagement and Emotional Responses *M. Plona*	Exploring the Influence of Prenatal Aneuploidy Screening on Maternal-Fetal Bonding: Development of a Theoretical Model *C. Hippman*
10:15 AM - 10:30 AM	Custom EPIC Work Queue to Improve Insurance Coverage of Genetic Testing *J. Howell*	Analysis of Downstream Revenue Generated by a Hereditary Cancer Syndrome Diagnosis *J. Huang*	Have You Ever Googled a Patient? Social Media Intersects the Practice of Genetic Counseling *N. Omaggio*	Emerging Issues with NIPT: Genetic Counselors' Experiences and Perspectives with Incidental Findings *A. Orta*
10:30 AM - 10:45 AM	Clinician Education as a Vehicle for Improving High Risk Women's Path to Genetic Counseling: The Impact of Educational Interventions in Community Health Setting *S. Greenberg*	*BRCA2* Mutation Carriers May Present with Primary Brain Tumors: A Review of a Multigene Panel Testing Cohort *M. Jackson*	Improving Pre-Test Counselling for NIPT: Women's Enduring Misunderstandings after Pre-test Counseling *L. Little*	Whole Genome Sequencing for Ostensibly Healthy Individuals: Genetic Counseling Challenges and Early Experiences *M. Cochran*
10:45 AM - 11:00 AM	Information is Powerful: Experiences from a Population Screening Initiative for Inherited Breast and Ovarian Cancer Risk *K. East*	Unexpected Findings of Germline *CDH1* Mutations: Implications for Counseling Regarding Clinical Management *M. Fay Jacobs*	Prenatal Exome Sequencing: Issues of Clinical Utility and Beyond *B. Castro*	Patient Demographics in the Decision to Enroll or Decline Whole Exome Sequencing (WES) in the Pediatric Cancer Setting *K. Bergstrom*
11:00 AM - 11:15 AM	Establishing a Virtual Telegenetics Clinic for Cancer Genetic Counseling: Challenges and Solutions *N. Keshavan Reddy*	How Narrow the Divide: Cross Lab Concordance for Expanded Inherited Cancer Panel Genes in ClinVar *M. Judkins*	'To Disclose or Not to Disclose': An Investigation of Counselor Self-Disclosure in the Field of Genetic Counseling *B. Volz*	Adolescent and Parent Perceptions of Disorders of Sex Development: A Brief Insight *L. Williams*

CONCURRENT PAPERS

Saturday, October 1

1.50 Contact Hours

	D10: Building the Genetic Counseling Workforce • Explore the use of social media/online platforms as genetic education tools. • Define factors impacting genetic counseling professional growth/development. • Identify emerging professional genetic counseling opportunities.	**D11:** Genetic/Genomic Testing II • Explore the unique roles of lab-based genetic counselors. • Develop tools to address variables impacting effective genetic/genomic testing. • Classify emerging genetic/genomic testing methods.	**D12:** Adult Genetics • Explore unique challenges in providing genetic counseling to adult patients. • Describe how to tailor care to clinical subpopulations. • Identify the ways in which genetic counselors can provide expanded care. Sponsored by: Asuragen®	**D13:** Counseling/ Psychological Issues • Explore unique challenges in providing genetic/genomic testing. • Develop frameworks for expanding and evaluating genetic counseling practice. • Identify novel ways of addressing patients' clinical/emotional needs.
	Room 615 - 617	Room 611 - 614	Room 608 - 609	Room 606 - 607
1:00 PM – 1:15 PM	Movement of Genetic Counselors from Clinical to Non-Clinical Positions: A National Workforce Survey *S. Cohen*	Is Bigger Always Better? Small Sequencing Panels versus Large Scale Next-Generation Sequencing Panels in Genetic Testing for Arrhythmogenic Right Ventricular Cardiomyopathy *B. Murray*	Patients with Amyotrophic Lateral Sclerosis Have High Interest in and Limited Access to Genetic Testing *K. Wagner*	Patient Expectations for Non-Diagnostic Whole Exome Sequencing *R. Hylind*
1:15 PM – 1:30 PM	Ask Us Anything! The National Society of Genetic Counselors Expert Media Panel Meets Reddit AMA *E. Ramos*	Expansion of the Laboratory Genetic Counselors Role: Utilization of Laboratory-Based Genetic Counselors to Build Unique Patient – Specific Phenotype Panels *S. Everhart*	Low *FMR1* CGG Repeat Length in Males is Associated with Family History of *BRCA*-Associated Cancers *H. Adamsheck*	A Health Beliefs Model Investigation of Fetal Echocardiography Uptake in Mothers of Children with Congenital Heart Defects *S. Fitzgerald-Butt*
1:30 PM – 1:45 PM	Flipping the Classroom and the Clinic: Meeting the Needs of the Expanding Genetic Counseling Workforce through Online Branching Case Studies *A. Cummings*	A Single-center Experience with Clinician Interpretation of Variants in Cardiovascular Genetics Indicates Clinically Impactful Disagreement with Testing Laboratories *A. Bland*	Exploration of Communication Strategies Used by Support Persons in Facilitating Cognitive and Emotional Processing of Information Within Alzheimer's Disease Risk Disclosure Visits *L. Erby*	Family History and Clinical Severity Predict Cardiac Anxiety in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy and Their At-risk Family Members *C. James*
1:45 PM – 2:00 PM	Do Genetic Counseling Programs "Like" Facebook? *T. Lepard Tassin*	The Current and Future Contributions of Genetic Counselors in the Field of Lifestyle Direct-to-Consumer Genetic Testing: an Exploratory Study *H. Green-Morfesi*	Clinical Cardiac Screening of Hypertrophic Cardiomyopathy is Less Critical for Family Members of Mutation-Negative Cases C. Ko	Long-Term Impact of Genetic Testing Reporting on Understanding and Prioritization of Risk Information *W. Kohlmann*
2:00 PM – 2:15 PM	Exploring the Role of Genetic Counselors in Tumor Genomic Sequencing *M. Weinberg*	Genesurance: The Mysterious Element of Genetic Counseling *S. Brown*	Genetic Counseling for Alopecia Areata: Recurrence Risks of Alopecia Areata and Other Associated Conditions in First-Degree Relatives *K. Agre*	Validation and Extension of the Reciprocal-Engagement Model of Genetic Counseling Practice: A Qualitative Investigation of Genetic Counselor Goals, Strategies and Behaviors *K. Redlinger-Grosse*
2:15 PM – 2:30 PM	Why Do Genetic Counselors Consider Changing Jobs? A National Workforce Study *S. Cohen*	Personal and Family History in Patients with High Penetrance Germline Findings through Paired Tumor/Normal Sequencing *K. Hanson*	Creating a Medically Actionable Genetic Screening Panel for Healthy Individuals *E. Haverfield*	Effect of Photographs of Visible Genetic Conditions on Quality of Life Perceptions *C. Falugi*

Integrated Genetics offers you a *choice* in genetic testing.

Please visit
Integrated Genetics booth #300
to learn about our genetic tests.

Every patient comes from a different background with a unique personal and family medical history. The better test to choose is one that, to a greater extent, matches the needs of the patient based on the complete medical history.

Reproductive Test Choices

- **Inheritest® Carrier Screen** including CF*plus*®, spinal muscular atrophy, and fragile X
- **informaSeq®** non-invasive prenatal test (cfDNA)
- **Maternal Serum Screening** – First*Screen*®, Sequential*Screen*℠ and Integrated*Screen*℠
- **Prenatal Diagnostics** of chromosome abnormalities
- **Reveal® SNP Microarray** for prenatal, post-natal, and POC specimens

Hereditary Cancer Test Choices

- BRCA*ssure*® *BRCA1/2* Testing
- VistaSeq℠ Hereditary Cancer Panel

Integrated Genetics is committed to providing comprehensive care to you and your patients.

To learn more about Integrated Genetics and our range of tests, please visit **booth #300 in the exhibitor suite.**

Integrated GENETICS
LabCorp Specialty Testing Group

informaSeq® Prenatal Test is Powered by Illumina® sequencing technology.

POSTERS WITH AUTHORS

Objectives:

- Recognize varied approaches to building an evidence base to support best practices in genetic counseling.
- Identify opportunities for the genetic counseling community to expand the reach of genetic/genomic-based care.
- Evaluate the varied settings in which genetic counseling expertise is utilized.

A09 Group A Posters
Wednesday, September 28
6:15 PM – 7:30 PM
1.25 Contact Hours

B18 Group B Posters
Thursday, September 29
5:45 PM – 7:00 PM
1.25 Contact Hours

C08 Group C Posters
Friday, September 30
11:30 AM – 12:45 PM
1.25 Contact Hours

WEDNESDAY POSTERS

Access/Service Delivery

A-1 Working with the Hmong population in a genetics setting: Genetic counselor perspectives
A. Agather

A-4 Genetic counselor workflow study: The times are they a-changin'?
C. Attard

A-7 Implementing multiple service delivery models to increase access to care: Experiences of a community genetics program
L. Bucheit

A-10 The newly redesigned genetics home reference website as a genetic counseling aid
H. Collins

A-13 Health care access in Wisconsin Amish and old order Mennonite populations: A comparative study
J. Elliott

A-16 Experiences of genetic counselors practicing in rural areas
M. Emmet

A-19 Who orders whole exome sequencing and why: Review of 181 preauthorization requests
G. Fraley

A-22 "Now what do I do?": A qualitative study of primary care providers and microarray analysis results of uncertain significance
C. Guy

A-25 Development of tools to determine communication strategies for actionable genes from ClinGen's CADRe Working Group
M. Hallquist

A-28 Scalable genetic counseling in the era of whole genome sequencing
W. Kelley

A-31 The establishment of the professional society of genetic counselors in Asia: A report from the genetic counseling pre-conference workshop held at the 11th Asia-Pacific conference on human genetics in Hanoi, Vietnam
M. Laurino

A-34 Evaluation of an online educational tool for carrier screening
J. Lee

A-37 Scaling genetic counseling: A human-centered approach to creating an electronic GC platform
E. Levin

A-40 The production of prenatal genetic testing educational videos for patients
H. Lindh

A-43 The changing landscape of genetic counselors licensed in Washington state (2011-2015)
A. Mackison

A-46 Supporting young adults with neuromuscular disease with a new transitions tool
A. McArthur

A-49 Genetic counseling services in a patient centered medical home
P. Robbins-Furman

A-52 A qualitative evaluation of the Pennsylvania Department of Health Down syndrome fact sheet
E. Royer

A-55 International genetic telehealth: A case series demonstrating value in rare disease diagnosis
J. Ruschman

A-58 Diagnostic yield using next generation sequencing techniques in the hearing loss population
I. Shepard

A-61 Weathering the storm: Genetic counselor satisfaction in the age of genomic medicine
C. Spaeth

A-64 Increasing awareness of genetic counseling: A lesson plan for high school biology teachers
S. Turner

A-67 Adults are not big kids: Adults undergoing whole exome sequencing represent a unique clinical population
R. Willaert

Cancer

A-70 A community mammography high risk screening program: A precautionary tale
N. Armstrong

A-73 "Incidental" germline finding following somatic molecular profiling
L. Bokovitz

A-76 Longitudinal natural history of dermal neurofibromas in individuals with Neurofibromatosis Type 1
A. Cannon

A-79 Multigene genetic testing for hereditary cancer susceptibility in the community setting: Do patients prefer more?
J. Christiansen

POSTERS WITH AUTHORS

A-82 Development of an iPhone application to support tracking and adherence to recommended guidelines for women with a BRCA mutation
S. Cohen

A-85 A needs assessment for the development of a hereditary breast cancer syndrome support group in Greensboro, North Carolina
K. Garbarini

A-88 Patient participation in family studies: A collection of semi-structured interviews
L. Garrett

A-91 The importance of cascade screening: Lessons learned from a family with Atypical Multiple Endocrine Neoplasia Type 1
K. Guthrie

A-94 The role of genetic counselors in education and communication about cascade testing for hereditary cancer syndromes
R. Hagen

A-97 The genetic counseling assistant: Dana-Farber's experience in establishing a new role
C. Heydrich

A-100 Use of tumor histology to aid the identification of patients with Lynch syndrome
C. Mauer

A-103 Expanding the phenotype of *DICER1* syndrome: Two years of *DICER1* testing in a pediatric cancer genetics clinic
R. McGee

A-106 Improved uptake and efficiency of genetic counseling services via an embedded genetic counselor in a multidisciplinary breast cancer clinic
R. Noss

A-109 Cascade testing for hereditary cancer syndromes: Beyond Lynch and *BRCA*
J. Osborne

A-112 Genetic counseling for lung cancer
E. Palen

A-115 Genetic counselors and physicians play separate but important roles in cancer risk management decision making
A. Puski

A-118 Assessing clinician confidence and preferences when incorporating genomics in the pediatric oncology clinic: Insights from an institutional survey
E. Quinn

A-121 *CDH1* in the era of multigene panel testing: Discrepancies between the literature and observed phenotypes for missense variant carriers
M. Roberts

A-124 Germline implications of somatic tumor profiling and the evolving role of genetic counselors in oncology: A case series
B. Roscow

A-127 The psychosocial effects of the Li-Fraumeni education and early detection program on individuals with Li-Fraumeni syndrome
J. Ross

A-130 Preliminary baseline data from the scheduling of necessary advised procedures (SNAP) for *BRCA* iPhone application
C. Scherr

A-133 Case report: Phenotypic expression related to a germline *POLD1* mutation in a large expanded pedigree
B. Smith

A-136 A case report illustrating the utility of DNA banking, an underutilized genetic counseling strategy
K. Stoll

A-139 Incidental or not so incidental finding…that is the question: Tumor profiling leads to germline *FANCA* mutation identification in a male breast cancer patient
H. Vig

Cardiology

A-142 Inherited cardiomyopathies in the pediatric population: What molecular testing reveals
S. Aguilar

A-145 Clinical cardiovascular genetic counselors take a leading role in team-based variant interpretation
C. Caleshu

A-148 Uptake of presymptomatic genetic testing and cardiac screening for children at risk for an inherited arrhythmia or cardiomyopathy
S. Christian

A-151 Reportable variants in genes less commonly associated with cardiomyopathies
R. Latimer

A-154 *De novo* variant rate in pediatric hypertrophic cardiomyopathy
E. Miller

A-157 Assessing medical examiners' current practices in utilizing genetic testing for autopsy-negative sudden unexpected death in the young
L. Moissiy

A-160 Numeracy and genetic knowledge's effect on perceived recurrence risk of congenital heart defects
K. Myers

A-163 Hypertrophic cardiomyopathy genotype prediction models in a pediatric population
R. Newman

A-166 Universal screening for elevated cholesterol in children: Assessment of awareness of and adherence to guidelines among Ohio pediatricians
A. Onorato

A-169 Left ventricular noncompaction cardiomyopathy and genetic syndromes
A. Parrott

A-172 Compound heterozygous *NARS2* mutations identified by whole exome sequencing in two sibs with infantile-onset mitochondrial multiorgan failure
J. Propst

A-175 Baseline knowledge of lipids and risk perception in patients with probable familial hypercholesterolemia or a previous diagnosis
A. Raper

A-178 *SMAD2* associated with thoracic aortic aneurysms and dissection found on whole exome sequencing for a child with a congenital heart defect
C. Rigelsky

A-181 Prevalence and natural history of aortic root dilation in a longitudinal cohort of patients with Ehlers-Danlos syndrome Hypermobility Type
A. Ritter

POSTERS WITH AUTHORS

Counseling/Psychosocial Issues

A-184 Anticipated impact of children's genetic test results on the parent-child relationship
L. Bailey

A-187 Where does hope fit in? The relationship between hope, uncertainty and coping efficacy in mothers of children with Duchenne/Becker Muscular Dystrophy
M. Bell

A-190 Patient perspectives on intimate partner violence discussion during genetic counseling sessions
C. Chen

A-193 Information needs of patients and their caregivers: Utility of genetic counselors
M. Dudek

A-196 Diagnosis of X-linked intellectual disability in an adult female via exome sequencing: A collaborative diagnosis between clinician and laboratory
S. Galasinski

A-199 Attitudes toward genetic counseling and testing in patients with inherited endocrinopathies
T. Gallagher

A-202 Patient and parent experiences of dual genetic diagnoses: Neurofibromatosis Type 1 and an additional genetic disease
H. Grandine

A-205 Moderating effects of trait hope and coping styles on perceived personal control in genetic counseling
M. Hackbardt

A-208 Shared medical and psychosocial concerns among adolescents and young adults with craniofacial microsomia: A qualitative study
K. Hamilton

A-211 Alzheimer's disease development in adults with Down syndrome: A caregiver's perspective
A. Ilacqua

A-214 Understanding the challenges of underrepresented minority recruitment (URM) into genetic counseling: A qualitative study of URM individuals currently in the profession
A. Kass

A-217 GenomeConnect participant matching system: Connecting individuals with rare diseases or genomic variants
J. Koenig

A-220 Genetic counseling for reproductive fitness in Fabry disease
D. Laney

A-223 Genetic counseling of hearing loss: Where we've been and where we're going
S. Noon

A-226 The impact of treatment on reproductive decisions in Fabry disease
S. Pass

A-229 Innovative Genetic Genealogy LHON pilot program
L. Poincenot

A-232 "A closer look"– Benefits and challenges to receiving obstetric care in the workplace as a pregnant prenatal genetic counselor
J. Rietzler

A-235 The patient's perspective: Is there a role for religious spiritual assessment in genetic counseling?
L. Rogers

A-238 The informational and emotional support needs of grandparents of children with Pompe disease
N. Rudy

A-241 Family impact of 1p36 deletion syndrome
R. Sheikh

A-244 Attitudes towards facial transplants among individuals with neurofibromatosis
D. Singman

A-247 Ramifications of neurofibromatosis on self-esteem
D. Singman

A-250 The impact of hyperphagia and food restriction on siblings of individuals with Prader-Willi syndrome
E. Wishnefsky

Education

A-253 Identifying and counseling patients amenable to mutation specific therapies in Duchenne Muscular Dystrophy: Knowledge of resources will fuel genetic counselors' impact
L. Bogue

A-256 Incorporation of a genetics-based information module into standardized diabetes patient education
K. Drazba

A-259 Family health history communication: Cross-cultural comparison of knowledge of familial disease history
A. Elrick

A-262 "If I saw this, I would feel well-informed" to "in a word, it was awful": Evaluation of a novel educational video on pharmacogenetic testing
M. Ensinger

A-265 Development and validation of a knowledge-based questionnaire to assess comprehension of genetic counseling on advanced maternal age
C. Garcia

A-268 Online educational information of monogenic diabetes: Which websites should genetic counselors recommend?
Y. Guan

A-271 The impact of patient education on understanding of cfDNA screening among pregnant women in a general risk population: The Rhode Island experience
E. Kloza

A-274 An assessment of genetic provider and parent communication patterns in genetic counseling sessions
N. Lahner

A-277 Capitalizing on the genetic counselor role in the implementation of a lab utilization management model focused on providing education, guidelines and clinical support for non-genetic providers surrounding genetic test navigation and interpretation
E. Leeth

A-280 Factors influencing admission into genetic counseling programs
L. Lipe

A-283 Success of NIPT based on maternal weight and gestational age
R. McCullough

A-286 Knowledge and confidence of genetic counselors with state laws and training for managing the option of abortion in the setting of fetal anomalies
S. Rhine

POSTERS WITH AUTHORS

A-289 Cystic fibrosis-related infertility: Thoughts and experiences of men in romantic relationships
M. Sikes

A-292 Low fetal fraction prevents detection of fetal triploidy by cell-free DNA screening
B. Tucker

A-295 Storytelling and family communication about Type 2 diabetes in an urban Appalachian community
K. Warsinske

Genetic/Genomic Testing

A-298 The utility of genomic variant databases in genetic counseling
E. Brokamp

A-301 Genotype-phenotype correlation of individuals with chromosome 8p23 duplication or deletion syndromes
C. Burden

A-304 15q overgrowth syndrome: A possible new diagnosis with the smallest reported duplication associated with an overgrowth phenotype
J. Diaz

A-307 Novel pathogenic variant in *HNRNPK* identified in a female with Au-Kline syndrome
E. Fanning

A-310 Genetic counselor consent reduces ancestry-related differences in choice to receive secondary findings in a large-scale genomic sequencing study
K. Fiallos

A-313 Experiences of exome sequencing in newborns: A peek into BabySeq
C. Genetti

A-316 Further clinical delineation of *PACS1*-Related syndrome: A recurrent *de novo* pathogenic variant
J. Hoffman

A-319 Further evidence of a likely pathogenic variant in *TWIST1* as causative of Saethre-Chotzen syndrome
C. Hollinger

A-322 A comparison of self-reported ethnicity and genetic ancestry
K. Kaseniit

A-325 Keeping somatic mosaicism in the differential: The diagnosis of Schimmelpenning-Feuerstein-Mims syndrome through skin biopsy
L. Kehoe

A-328 *MAP3K1* mutations are a common cause of 46, XY gonadal dysgenesis
L. Mohnach

A-331 Regions of homozygosity: Implications on testing and counseling strategies
R. Mostafavi

A-334 Decreasing healthcare costs: Turnaround time reduction
M. Nelson

A-337 Secondary findings in trio family members of probands undergoing diagnostic exome sequencing
Z. Powis

A-340 Continued coverage and reimbursement challenges for diagnostic exome sequencing after 5 years, genetic counselors can help to overturn denied cases
Z. Powis

A-343 Navigating neurometabolic disorders: Uncovering a rare X-linked recessive disorder in a heterozygote female
C. Rajakaruna

A-346 Diagnostic yield of genetic testing at the Children's Hospital Colorado autism genetics clinic
H. Raszka

A-349 Development of a test quality assessment tool: A professional resource for genetic counselors
J. Riley

A-352 Facilitating human disease gene discovery through intersection of chromosomal microarray and whole exome sequencing data
J. Rosenfeld

A-355 Pediatrician practice regarding the genetic evaluation of children with autism spectrum disorder
A. Rutz

A-358 Association of airway abnormalities with 22q11.2 deletion syndrome
R. Sacca

A-361 Whole exome sequencing identifies a pathogenic variant in *TSC1* in a father and son without typical findings of Tuberous Sclerosis Complex
A. Schreiber

A-364 Novel finding of complete paternal uniparental isodisomy 4 in a girl with a complex congenital heart defect and bilateral optic nerve hypoplasia
A. Shealy

A-367 Parental understanding of whole exome sequencing: A comparison of perceived and actual understanding
L. Tolusso

A-370 Use of next-generation sequencing to diagnose concomitant hemolytic anemia in children with sickle cell disease
E. Varga

A-373 *De novo* deletion of *GATAD2B* putative regulatory region associated with clinical features consistent with *GATAD2B* haploinsufficiency
K. Wain

A-376 Sequencing the coding exon of *GJB2* may be a better testing strategy for familial cases of autosomal recessive nonsyndromic hearing loss: A case report
E. Wakefield

A-379 Test utilization and the role of genetic counseling in pediatric hematology at a tertiary care center
K. Zajo

A-382 Genetic test utilization management: Trends of decreasing costs of genetic test orders
L. Zetzsche

THURSDAY POSTERS

Access/Service Delivery

B-2 Utility of a patient-facing family health history assessment tool to refer patients for genetic evaluation
L. Baumgart

B-5 Genetic testing for hereditary cancer predisposition: When can a targeted discussion with a non-genetics clinician provide adequate consent?
A. Buchanan

B-8 Attitudes about the use of internet support groups and the impact among parents of children with Cornelia de Lange syndrome
C. Cacioppo

POSTERS WITH AUTHORS

B-11 Video-assisted genetic counseling in patients with ovarian, fallopian and peritoneal cancer
R. Covington

B-14 Utilizing contracted telephone genetic counseling services within an established cancer genetic counseling clinic: Benefits and drawbacks
D. Cox

B-17 Establishing a multidisciplinary hereditary cancer risk management clinic
A. Forsha

B-20 Client perspectives on the utilization of genetic services in a community-based hereditary cancer screening program
S. Greenberg

B-23 Referral of triple negative breast cancer patients to cancer genetics services in the community setting
J. Handy

B-26 Increasing genetic counseling referral among gyn oncology registry patients meeting NCCN guideline criteria: A collaborative approach
K. Huelsman

B-29 Why is cancer genetic counseling underutilized by women identified as at risk for hereditary breast cancer? Patient perceptions of barriers following a referral letter
A. Kne, BS

B-32 Development and implementation of breast and ovarian cancer test criteria for a next generation sequencing panel within a large health maintenance organization
C. Kobelka

B-35 Attitudes towards interpretation services provided to underserved patients during cancer genetic counseling sessions in the public hospital setting: Perspectives from genetic counselors and interpreters abstract
K. Lara-Otero

B-38 Clinical cancer genetic testing in Singapore: A single-institution experience
S. Li

B-41 Health information technology in clinical genetic counseling: A multi-specialty survey project
W. Mendonca

B-44 Prenatal testing in pregnancies established through in vitro fertilization in the era of noninvasive prenatal testing
L. Palange

B-47 Use of technology solutions increases efficiency of genetic counseling for hereditary cancer
L. Servais

B-50 Genetic counseling clinic: Expanding genetic services to the pediatric population
K. Siefkas

B-53 Who are the cardiologists early to adopt integration of genetic counselors into clinical practice?
K. Spoonamore

B-56 Factors associated with breadth of multigene panel testing selected by patients at risk of hereditary breast and ovarian cancer syndrome: A cohort study
J. Szender

B-59 Navigating underinsured women from mammography to genetic counseling: Challenges and possibilities
E. Watson

Cancer

B-62 Racial variation in the frequency and genotype–phenotype correlations of *MLH1*, *MSH2*, *MSH6*, and *PMS2* gene mutations; and performance of *PREMM1,2,6* in ethnically diverse individuals: A cross-sectional study
R. Alsulaiman

B-65 Factors influencing uptake of risk-reducing salpingo-oophorectomy by *BRCA1* and *BRCA2* mutation carriers
V. Breen

B-68 Factors predicting *BRCA1* and *BRCA2* mutation carriers' preference for communication of risk estimates
S. Crowdes

B-71 Favorable psychosocial outcomes in high or moderate risk mutation carriers identified by hereditary cancer panel testing
J. Culver

B-74 The importance of discussing lifestyle risk factors in cancer genetic counseling
V. Dickens

B-77 Unaffected women's decisions to have prophylactic risk-reducing mastectomies
S. Galloway

B-80 Single nucleotide polymorphism (SNP) testing in breast cancer risk (BCR) assessment: Patient interest, knowledge and education
C. Heydrich

B-83 Oncologists' awareness, understanding and usage of germline NGS-based multigene panel tests for heritable cancer susceptibility in patients and their families
C. Kurpad

B-86 Pre-test genetic counseling as a requirement for germline hereditary cancer testing: What do patients do?
G. Lazarin

B-89 Genetic counseling complexities of *CHEK2* positivity: Medical management implications for patients and families
C. Lewis

B-92 Endometrial cancer risk perception in women diagnosed with Lynch syndrome
M. Lubaton

B-95 Patient-reported clinical outcomes and personal perspectives after risk reducing surgery
C. Mauer

B-98 Unexpected *CDH1* mutations in probands with non-lobular breast cancer
S. Rao

B-101 Lynch syndrome phenocopy identified by novel tumor/normal technique for identifying sporadic mutations
M. Rashkin

B-104 Through the eyes of the patient: Understanding variants of uncertain significance in the era of multi-gene panels
C. Reuter

B-110 Penetrance of a rare familial gene predisposing to papillary thyroid cancer
D. Saporito

B-113 A "second class status": The experience of men with *BRCA* mutations
A. Suttman

POSTERS WITH AUTHORS

B-116 "A change in perspective": Exploring the experiences of adolescents with hereditary tumor predisposition
E. Weber

B-119 Genetic counseling and companion diagnostics for PARP inhibitors
K. Wilson

Cardiology

B-122 Significance of family history in amyloidosis subtyping
E. Brown

B-125 Athletic adults with hypertrophic cardiomyopathy have difficulty adapting to exercise recommendations
C. Caleshu

B-128 Expanding the phenotype in patients with TGFβ-pathway disorders including arterial beds affected: Experience of a tertiary care center
D. Clements

B-131 Examining psychological outcomes associated with genetic testing for primary arrhythmic disorders in adult patients
S. Colaiacovo

B-134 The impact of a long QT syndrome diagnosis on competitive athletes' psychological processes
B. DeGreef

B-137 The pediatric arrhythmia clinic: Identifying and addressing demand for genetic counseling and genetic services
B. Helm

B-140 How do carriers of Barth syndrome navigate reproductive options? An example of hidden fault lines for patient-based support organizations
C. James

B-143 Psychosocial concerns of patients with dilated cardiomyopathy
A. McFaddin

B-146 Assessing the perceived utility of a web-based educational video in hypertrophic cardiomyopathy patients for the dissemination of familial risk information and screening recommendations
C. Neumann

B-149 Truncating titin variant in infantile-onset dilated cardiomyopathy: A case report and related counseling challenges
B. Psensky

B-152 Left ventricular outflow tract obstructions: Parental knowledge and uptake of familial cardiac screening
A. Shikany

B-155 Evolving decisions about exercise among athletes with inherited heart disease who exercise against recommendations
T. Subas

B-158 Thinking outside the A-band: Segregation of *TTN* truncating variants
H. Taylor

Counseling/Psychosocial Issues

B-161 Whole exome sequencing following the finding of multiple skeletal anomalies on prenatal ultrasound
L. Aptekar

B-164 Secondary findings: Counseling and clinical implications following identification of microdeletions and microduplications during preimplantation genetic diagnosis
R. Cabey

B-167 Parental quality of life of Tyrosinemia Type I
H. Campbell

B-170 A psychologic survey of women and men who received a prenatal diagnosis of anencephaly: The impact of genetic counseling and patient recommendations
H. Cope

B-173 NIPT failure due to low fetal fraction: Redraw success and patient decision making in an urban population
M. Crawley

B-176 Pronounced micrognathia and other anomalies in a pregnancy with an unbalanced pericentric inversion 46,XX,der(8)del(8)(p23) dup(8)(q21)
M. Discenza

B-179 Clinical utility of expanded carrier screening: Reproductive behaviors of at-risk couples
C. Ghiossi

B-182 The benefit of genetic counseling in the preimplantation genetic screening decision
J. Isaac

B-185 Women's experiences with receiving the news of an abnormal prenatal ultrasound
B. Madden

B-188 Maternal age and pregnancy loss: It's not all about the trisomies
M. Maisenbacher

B-191 Factors associated with burnout in clinical genetic counselors
D. Martiniuc

B-194 Decisions and understanding of noninvasive prenatal testing in a county hospital population
V. Mathur

B-197 Genetic counseling outcomes and experiences with clinical whole genome sequencing in a healthy population
M. McGinniss

B-200 The importance of a genetic counselor as a team member in any tertiary care (fetal medicine) center
M. Menzel

B-203 Decision-making surrounding the use of preimplantation genetic diagnosis in couples at-risk for cystic fibrosis and spinal muscular atrophy
K. Miller

B-206 Establishing a comprehensive genetic counseling service for patients with inherited and acquired pediatric bone marrow failure
K. Schneider

B-209 Managing couple conflict during prenatal counseling sessions: An investigation of genetic counselor experiences and perceptions
K. Schoeffel

B-212 The addition of 22q11.2 deletion syndrome to NIPT: Clinical utility and patient decision making
S. To

B-215 Attitudes towards prenatal genetics among Southeast and East Asian women: A qualitative pilot study
G. Tsai

B-218 Duchenne Muscular Dystrophy population carrier screening outcomes in the U.S.
J. Wallace

POSTERS WITH AUTHORS

B-221 The frequency of incidental findings in expanded carrier screening
K. Wong

Ethical, Legal and Social Issues

B-224 Genetic testing and life insurance: A Canadian perspective
A. Bedard

B-227 A taxonomy of medical uncertainties in genome sequencing
B. Biesecker

B-230 Relatives and risk-reporting: An updated assessment of genetic counselors' perspectives
K. Boggs

B-233 Bias in genetic counseling: Where does it really live?
U. Canteenwalla

B-236 An assessment of the mitochondrial disease community's knowledge and perception of the "three-person baby," or mitochondrial replacement therapy, and the impact of the media debate that surrounds this technique
A. Fiss

B-239 Physicians' experiences with and attitudes toward non-medical sex selection through preimplantation genetic diagnosis
N. Harkavy

B-242 Gestational surrogacy: Decision making regarding prenatal testing and genetic counseling
S. Malca

B-245 NIPT results concerning for maternal neoplasm: Consideration of uterine fibroids
L. Murphy

B-248 Development of a consent resource for genomic data sharing in the clinical setting
E. Riggs

B-251 All in the family: The benefit of reporting carrier results in the pediatric population
J. Schuette

B-254 Participant perspectives on return of genetic research results in an ethnically diverse biobank
N. Zeid

Genetic/Genomic Testing

B-257 Outside the lines: Detection rate of chromosomal microarray in individuals without a 'guideline' indication for testing
A. Baxter

B-260 The utility of multi-gene sequencing in the diagnosis of congenital myasthenia and related neuromuscular disorders
K. Beattie

B-263 An individual with *BRIP1* and *DICER1* pathogenic mutations identified by whole exome sequencing trio analysis and multi-gene hereditary cancer panel testing: A case report
M. Blundell

B-266 Variant classification in an unaffected population, an example from expanded carrier screening and a comparison to ClinVar classifications
S. Candille

B-269 Direct-to-consumer return of genetic risk information for venous thromboembolism: Consumer interest and impact on health behaviors in the Impact of Personal Genomics (PGen) Study
E. Cousins

B-272 What counts? The role of numeracy in objective and affective risk interpretations after receiving a personalized genomic risk vignette
K. Davis

B-275 The impact of numeracy on genetic self-efficacy after receiving a personalized genomic risk vignette
K. Davis

B-278 Reclassification of a sequence variant from pathogenic mutation to variant of uncertain significance in a family with familial thoracic aortic aneurysm and dissection
H. Douglas

B-281 WES testing in families with high kinship coefficients: WES trio is more effective than focused regions of homozygosity analysis
L. Folk

B-284 Expanding the phenotype of 2p11.2-p12 deletion syndrome: A case report
L. Fuqua

B-287 Maternal age effect on euploid rates for reciprocal translocation carriers
J. Klavanian

B-290 Mammalian species conservation data and the implication for clinical variant classification
Y. Kobayashi

B-293 Exome sequencing in fetuses with abnormal ultrasound findings leading to demise or termination
C. Kucera

B-296 Efficacy of custom targeted gene lists as compared to whole exome sequencing
K. Levine

B-299 A retrospective review of family studies in reclassifying variants of unknown significance detected in cardiomyopathy multigene panels
I. Lu

B-302 Cystic fibrosis screening in the Asian population: What standard panels miss
C. Marks

B-305 Increase in diagnostic yield and detection rates of exome-based testing using complementary NGS platforms
B. Parks

B-308 Population-wide genetic testing in the adult population: What are people saying?
D. Samad

B-311 Factors that influence the completion of predictive testing for Huntington's disease
D. Schippman

B-314 Usher syndrome: Phenotypic characterization by type
D. Schlegel

B-317 Beyond clinical actionability: Minnesota residents' perceptions of important actions in response to genetic testing results
D. Seiffert

B-320 Trio-based whole exome sequencing: An effective diagnostic tool for patients with microcephaly
A. Shanmugham

B-323 An exploration of genetic counselors' personal decisions regarding genetic counseling and genetic testing
N. Sutherland

POSTERS WITH AUTHORS

B-326 Genetic screening practices for oocyte donors in the United States
G. VanNoy

B-329 When negative turns positive: The experience of diagnostic exomes that were initially non-diagnostic
A. Wadley

B-332 *USH2A* copy number variants in patients with heterozygous *USH2A* sequence variants
B. Williams

B-335 Novel hypomorphic *RAG2* variants in an adult with progressive myopathy and CVID
K. Wold

Professional Issues

B-338 Harnessing the potential of online and blended learning in graduate education programs
K. Anderson

B-341 Attitudes of veterans with PTSD toward a model used in psychiatric genetic counseling
J. Anderson

B-344 Nationwide genetic counseling programs: Challenges associated with disparate state laws
K. Fissell

B-347 "If it helps, it's worth a try": An investigation of perceptions and attitudes about genetic counseling among southern Manitoba Hutterites
A. Gemmell

B-350 Efficacy of antisense oligonucleotides in reducing Purkinje cell ataxin 1 RNA levels
H. Handler

B-353 Genetic counseling for alcohol use disorder: An assessment of need in affected and at-risk populations
F. Kalb

B-356 Perceptions of psychiatric genetic counselling in the mental health community: An exploratory study
N. Lemiski

B-359 Facilitating discussions about the psychiatric phenotypes of 22q11.2 deletion syndrome
J. Lent

B-362 The utility of non-traditional rotations in genetic counselor training
A. Markase

B-365 Changing with the times: How prepared do genetic counselors feel for non-clinical roles?
A. Narravula

B-368 Familial intracranial aneurysm: The prevalence and screening recommendations of one institution
K. Qualmann

B-371 Career advising about genetic counseling: A look at the current state of familiarity undergraduate career advisors have with genetic counseling
C. Rogers

B-374 An examination of the factors contributing to the expansion of subspecialty genetic counseling
V. Roth

B-377 One family, two distinct brain malformation disorders with different modes of inheritance
D. Stolar

B-380 Implementing compassion fatigue screening in genetic counseling practice
K. Wusik

FRIDAY POSTERS

Access/Service Delivery

C-3 The utility of nondirective and directive counseling styles in clinical practice from the perspective of certified genetic counselors
A. Bansal

C-6 EpiGC: A collaborative approach to an emerging professional and clinical need
A. Bergner

C-9 Establishing a committee to ensure appropriate utilization and standard provision of clinical exome sequencing at a pediatric tertiary care center
J. Conta

C-12 Overcoming challenges to provide genetics services in a county hospital system
D. Erwin

C-15 Genetic counselor referrals to hospital chaplains
A. Gregory

C-18 Additional skills required: Lessons learned through teaching telehealth
M. Hardy

C-21 Establishing a model for clinical exome sequencing (CES) coordination and pre-test counseling to ensure standard delivery of CES at a pediatric tertiary care center
E. Hendricks

C-24 The unique role of pediatric genetic counselors in a fetal health center
J. Kussmann

C-27 Are visual aids helpful in genetic telecounseling?: A case-control study
J. Miller

C-30 Interdisciplinary team approach as the ideal model for care of individuals with disorders of sex development
L. Mohnach

C-33 The value of a genetic diagnosis as perceived by intersex adults
T. Moscarello

C-36 When mating is not so random: Coupling patterns across ethnicities in the U.S. population
S. Nazareth

C-39 Cost of genetic screening influences patient decision making when weighing options of prenatal screening
L. Otto

C-42 Piloting a community genomics initiative using blood banks for recruitment and data collection
E. Ramos

C-45 Genotype-first genetic counseling: How general population genome screening has the potential to turn traditional genetics service models upside-down
M. Schwartz

C-48 When to take a family history: Assessing impact on genetic counseling outcomes
C. Slomp

C-51 Genetic counselors' perspective on the impact of Spanish-speaking interpreter-mediated sessions
R. Veazey

C-54 Difficult discussions: DNA banking
C. Zaleski

POSTERS WITH AUTHORS

Cancer

C-57 Assessing the possibility of *RUNX1* related germline predisposition in myeloid neoplasms in a somatic cancer setting
K. Barber

C-60 Characterizing the clinical cancer presentation of individuals with pathogenic variants in *FANCC*
J. Bissonnette

C-63 Mosaic variants in hereditary cancer genes identified on next generation sequencing panels
J. Bissonnette

C-66 Impact of FDA approval of PARP inhibitor treatment on genetic counseling and testing practices for ovarian cancer patients
K. Buchtel

C-69 Novel large rearrangement of *RAD51D* in an ovarian and breast cancer family
B. Burnett

C-72 Assessing VHL p.Pro81Leu- A low penetrance, pheo-predominant variant?
K. Dilzell

C-75 Types and frequencies of Lynch syndrome mutations identified through multigene panel testing
C. Espenschied

C-78 Breast and colorectal cancer risk in monoallelic *MUTYH* carriers ascertained via multigene panel testing
K. Fulk

C-81 Evaluation of two risk prediction models for patients with endometrial cancer seen in a hereditary cancer clinic
C. Garby Haskins

C-84 Design and enhanced validation of a 36-gene guideline-compliant inherited cancer panel
G. Gould

C-87 Suspected germline variants in snapshot NGS tumor genotyping and genetic counseling implications
K. Gravelin

C-90 Lost in translation: How medical interpreters modify the communication of whole exome sequencing results during translation for Spanish-speaking families
A. Gutierrez

C-93 *BRCA1/2* breast and ovarian cancer risks by variant location
S. Hiraki

C-96 When the family history leads you astray: A case report
J. Humanski

C-99 Unknown synergistic effect of digenetic inheritance of MMR pathogenic mutations: Double heterozygosity in Lynch syndrome, a single case report and family study
A. Jacquart

C-102 Confirmation of tumor biomarker results in the germline
M. Marshall

C-105 Outcomes of next-generation panel testing in adolescents and young adults with colorectal cancer
M. Mork

C-108 Panel testing reveals presence of likely pathogenic variants in *CDH1* in two probands with personal and/or family history of breast cancer. Subsequent gastrectomy confirms the presence of a diffuse gastric tumor in one of the unaffected probands
F. Oh

C-111 Multigene panels in prostate cancer patients with familial risk: Unexpectedly high mutation rates in *non-BRCA* genes
C. Radford

C-114 Identification of patients for genetic follow-up: Results from tumor gene profiles
B. Reys

C-117 Average age of diagnosis of ovarian cancer for women with pathogenic variants in *BRIP1*, *RAD51C* and *RAD51D*
S. San Roman

C-120 Variant rate by panel type across testing laboratories
A. Schmidt

C-123 Ancestry-based cancer risks associated with APC I1307K
L. Sharma

C-126 Fanconi Anemia (FA) type solid tumors in FA heterozygotes identified via inherited cancer gene testing
A. Stettner

C-129 All in the family: A first look at outcomes when multiple relatives undergo multi-gene panel testing
M. Umali

Counseling/Psychosocial Issues

C-132 Are genetic counselors screening for adolescent suicide risk? A mixed-methods study
C. Anderson

C-135 Parental experience of divulging a diagnosis of Fragile X syndrome to their affected child
B. Athens

C-138 The implementation of whole exome and genome sequencing based on genetic counseling specialty
A. Blesson

C-141 Adolescent decision-making regarding secondary findings in whole genome sequencing
R. Byrne

C-144 From a trio to a duo: Non-paternity identified through diagnostic exome sequencing
T. Cain

C-147 Diagnosis of Fragile X syndrome: A pre- and post-diagnosis comparison of carrier mothers' emotional and support experiences
A. Catchings

C-150 Patient preferences for recontact and their monitoring coping style following *BRCA* mutation testing
R. Dahle

C-153 A unique case of Down syndrome caused by nonmosaic Y;21 translocation
J. Foster

C-156 The psychosocial impact of diagnosis on caregivers of children with 3q29 deletion syndrome
M. Glassford

C-159 Communication predictors of patient and companion satisfaction with Alzheimer's disease genetic risk disclosure sessions
Y. Guan

C-162 Nationwide newborn screening program for mucopolysaccharidoses in Taiwan: Confirmatory diagnosis and genetic counseling
Y. Huang

C-165 A Delphi survey of personal utility
J. Kohler

POSTERS WITH AUTHORS

C-168 Direct and indirect non-disclosure preimplantation genetic diagnosis for Huntington's disease
A. Machaj

C-171 The needs and expectations of parents of children with rare conditions that are undergoing whole exome sequencing
J. Malcolmson

C-174 Discussing reproductive implications of exome sequencing findings with adolescents and their parents
R. Mueller

C-177 Unknown consanguinity reveals homozygous *CLCN7* mutations previously reported with autosomal dominant Osteopetrosis Type II: A case report
R. Nuccio

C-180 Paternal adaptation to a child's diagnosis of Down syndrome: Predictors of personal well-being and family quality of life
M. Oliver

C-183 Understanding the psychological impact of pediatric whole exome sequencing results on parents
R. Rabin

C-186 The undiagnosed patient and the diagnostic odyssey: Current genetic counseling practices and perspectives
A. Wardyn

Genetic/Genomic Testing

C-189 Comparing the clinical yield of carrier screening: Genotyping versus exon sequencing
K. Beauchamp

C-192 Intermediate *FMR1* CGG repeat sizes (35-54) may also contribute to fertility issues in women with potential premature ovarian insufficiency
T. Carter

C-195 A clinical perspective of sex chromosome abnormality screening via cell-free DNA
S. Detweiler

C-198 Indications associated with a prenatal diagnosis of Beckwith-Wiedemann syndrome
J. Ebrahimzadeh

C-201 NIPT results indicative of maternal neoplasms: Genetic counselors' awareness, preferences and attitudes
M. Giles

C-204 Lessons learned from a genome-scale carrier screening study: Implications for research and practice
M. Gilmore

C-207 How positive is your prediction? Computing confidence intervals on positive predictive value for non-invasive prenatal screening
I. Haque

C-210 What we are learning from studying balanced chromosome rearrangements at the nucleotide level
T. Kammin

C-213 A case of inherited copy number variant as explanation for multiple monosomies detected on NIPT
N. Krstic

C-216 Two cases of complete hydatidiform mole with coexisting live fetus identified by SNP-based cfDNA screen
N. Krstic

C-219 Preimplantation genetic diagnosis for maternally derived *de novo* mutation in the dystrophin gene (D,D)
A. Machaj

C-222 Partial 3q tetrasomy in an affected male fetus implicates dosage effect with an atypical lower urinary tract obstruction
S. Mulligan

C-225 Maximizing accuracy, clinical utility and patient experience of noninvasive prenatal screening via dynamic iterative depth optimization
D. Muzzey

C-228 1q21.2 microdeletion: An underreported cause of Nager syndrome?
S. Nassef

C-231 Should professional societies reconsider population-based carrier screening for Fragile X syndrome? A clinical testing laboratory's experience
K. Owens

C-234 Non-invasive prenatal screening: Everyone wants it, who's actually getting it?
N. Paolino

C-237 Fetal diagnosis of autosomal recessive primary microcephaly: A case for continued expansion of prenatal genetic testing
K. Patek

C-240 Prenatal testing for Noonan syndrome and related disorders: Data review and analysis
D. Wilson Mathews

C-243 Patient perception of residual risk post negative non-invasive prenatal testing
T. Wittman

C-246 Genetic testing for 46,XY disorders of sex development in a prenatal setting
A. wray

C-249 "Ashkenazi Jewish" conditions found in non-Jewish individuals
S. Yarnall

C-252 Clinician views on expanded newborn screening using whole genome sequencing
C. Young

Pediatrics

C-255 The association of functional disability and pain catastrophizing with healthcare utilization among individuals with Ehlers-Danlos syndrome hypermobility Type
K. Barfiwala

C-258 A complex X chromosome rearrangement in a female with tall stature and absent menses
A. Essendrup

C-261 Hypocalcemia and full scale IQ in 22q11.2 deletion syndrome
K. Grand

C-264 CHARGE Syndrome Clinical Database Project: ENT findings are common and affect development
M. Hefner

C-267 CHARGE syndrome: The importance of inner ear MRI and *CDH7* testing for diagnosis as the dysmorphology is not always obvious
M. Hefner

C-270 Disorders for inclusion in newborn screening: Health care providers' preferences
H. Peay

C-273 Congenital anomalies in infants of diabetic mothers: A silent epidemic
S. Ramanathan

POSTERS WITH AUTHORS

C-276 Reflections on the current state of healthcare transition for young adult women with Turner syndrome: Strategies for facilitating autonomy and self-management
M. Snyder

C-279 No difference in health related quality of life between therapeutic options for Type 1 Gaucher disease
V. Wagner

C-282 Using the Sanfilippo syndrome registry to find the patients for natural history studies and clinical trials
J. Wood

C-285 Expanding the phenotype of Oculofaciocardiodental syndrome: Report of two patients with novel retinal findings
K. Zegar

Pre- and Perinatal

C-288 Maternal folate levels in pregnancies preceded by short interpregnancy intervals and risk for infants born small for gestational age: Information to guide genetic counseling practice
P. Carrion

C-291 Certified nurse midwives' experiences with prenatal genetic screening
S. Dettwyler

C-294 Genetic counseling for preimplantation genetic screening
L. Dobson

C-297 Prenatal carrier screening acceptance rates in adopted individuals
K. Fissell

C-300 "What's in a name?" An assessment of knowledge about reproductive technology among young adults at risk for Huntington's disease
L. Hogan

C-303 Should genetic counselors have a well-defined role on a multidisciplinary perinatal palliative care team? Literature review and discussion of an opportunity to capitalize on a unique area of advancement for the field of genetic counseling
M. Jones

C-306 Maternal sickle cell disease may increase risk for cell free DNA based aneuploidy screening failure
K. Levandoski

C-309 Stress, anxiety and adaptation to genetic information: Parental experiences receiving a prenatal diagnosis of Klinefelter syndrome
K. Lewis Widmeyer

C-312 Discordant prenatal cell-free DNA screening results: A consideration of maternal and fetal incidental findings
M. Maxwell

C-315 Obstetric providers' experience with, interpretation of, and communication of NIPS test results
P. Sawla

C-318 The value of genetic counseling evaluation of prospective egg donors
E. Schlenker

C-321 The Kate Cares Stillbirth Assessment Program: A reevaluation utilizing SCRN assessment guidelines
H. Schuster

C-324 Genetic counselors' knowledge of and assessment for eating disorders in a prenatal setting
K. Sesock

C-327 The changing landscape of prenatal testing: Certified nurse midwives' integration of NIPT into practice
L. Weingarten

C-330 An assessment of expansion in Fragile X syndrome premutation carriers undergoing preimplantation genetic diagnosis and an exploration of psychosocial implications
N. Williams

Professional Issues

C-333 Characterizing pediatric narcolepsy: Family history and familial autoimmunity
H. Balka

C-336 Facing the challenge of genetic counselors' need for education about genomic technologies: Opportunities for improvement in training for genetic counselors
K. Banks

C-339 Connecting on Twitter to expand our reach: An analysis of the genetic counseling hashtag, #GCchat
L. Bucheit

C-342 High frequency of mosaicism in genes associated with epilepsy and neurodevelopmental disorders
E. Butler

C-345 Referrals to mental health services: Exploring the referral process in genetic counseling
M. Cunningham

C-348 Establishing a combined clinical and laboratory genetic counseling student rotation- The Seattle Children's Hospital experience
K. Golden-Grant

C-351 Adaptation of the G.I.F.T. technique as a tool for qualitative program evaluation
C. Guy

C-354 The contribution of the rs55705857 G allele to familial cancer risk using the Utah population database
S. Hummel

C-357 Impact of an educational intervention on undergraduate students' interest in pursuing a career in genetic counseling
R. LeShay

C-360 To be a clinical or non-clinical genetic counselor, that is the question
S. Liberman

C-363 The prevalence of asymptomatic focal cortical dysplasia and predictors of epilepsy severity in a pediatric cohort
L. Maynard

C-366 Application of genetic counseling graduate training to job responsibilities for entry-level, non-clinical genetic counselors
S. Nalbandian

C-369 X-linked Mohr-Tranebjaerg syndrome: Variable phenotype in females
H. Newman

C-372 What is a laboratory genetic counselor? The GeneDx experience
J. Nieto

C-375 A recurrent *GABRG2* variant associated with early-onset seizures, intellectual disability, motor and speech delays, and hypotonia
L. Schmidt

C-378 A case of presumed *RYR1* myopathy in a neonate and subsequent genetic counseling
C. Siskind

VENDOR-SPONSORED PRESENTATIONS

Vendor-sponsored presentations are 30-minute presentations given by select vendors in the Vendor Theater located in the AEConnect area of the Exhibitor Suite. These presentations are a great way to learn more about new products and services. Make the most of your time in the Exhibitor Suite by attending one of the following presentations:

Wednesday, September 28

6:15 PM – 6:45 PM

CancerIQ

Three Ways to Improve your Clinical Impact Through Technology

Andrea Downing, Business Development, CancerIQ

Technology today cannot only enable clinical teams to preempt and predict an individual's risk of developing cancer, but also actively engage with patients at every stage of the process to actually promote preventative care. With all the new tools available to automate cancer risk assessment, how can technology help genetic counselors to deliver a better clinical impact? Join moderator Andrea Downing and our panel of genetic counselors who are changing the way preventative cancer care is being delivered using CancerIQ. The panelists will discuss three practical ways to improve the impact of genetic counseling using technology.

7:00 PM – 7:30 PM

PREVENTION GENETICS

DISEASE PREVENTION THROUGH GENETIC TESTING

Difficult Discussions Surrounding DNA Banking

Christina Zaleski, MS, CGC

By combining clinical counseling experiences with patient feedback, we've developed some tips and conversational tools to enhance genetic counseling discussions on DNA banking, which often occur in difficult situations. Our hope is that this session will empower and motivate attendees to routinely discuss DNA banking with patients.

7:45 PM – 8:15 PM

Shire

The Evolving Role of the Genetic Counselor in the Multidisciplinary Approach to Lysosomal Storage Disease (LSD) Care

Abigail Hata, MS, CGC, Oregon Health and Science University

This session will focus on the multidisciplinary approach to LSD care from the perspective of the genetic counselor. The evolution of the genetic counselor's role and perspectives on needs along the patient journey will be highlighted, along with a discussion on earlier diagnosis and screening of Gaucher disease and other LSDs.

Thursday, September 29

5:15 PM – 5:45 PM

Seattle Children's HOSPITAL • RESEARCH • FOUNDATION | PLUGS® Pediatric Laboratory Utilization Guidance Services

Genetic Counselors and UM: Having the Courage to Do the Right Thing

Michael Astion, MD, PhD, Medical Director, Department of Laboratories, Seattle Children's Hospital and Pediatric Laboratory Utilization Guidance Services (PLUGS); Jessie Conta, MS, LCGC, Laboratory Genetic Counselor, Supervisor, Department of Laboratories, Seattle Children's Hospital and Pediatric Laboratory Utilization Guidance Services (PLUGS)

Utilization management (UM) interventions increase the value of testing, while reducing financial liability for patients, institutions and payers. Genetic counselors are courageous UM leaders, serving as detectives, educators, negotiators and advocates. Learn about efforts to harmonize medical necessity and optimize insurance coverage in the spirit of genetic stewardship.

6:00 PM – 6:30 PM

fulgent

New Standard of Cancer Testing Offered by Fulgent Diagnostics

Patricia Page, MS, CGC

Two sizes, infinite possibilities. Fulgent Diagnostics offers focused and comprehensive cancer panels with 99.99% coverage of coding and flanking intronic regions at minimum 50x depth. Start with one panel and customize it around the needs of your patient. Request results for any combination at no extra cost. This is the new standard of cancer testing.

6:45 PM – 7:15 PM

Shire

Learning to Trust Again: Common Issues Clinical Trial Participants Face When Transitioning Back to Routine Clinical Care

Laurie Bailey, MS, Coordinator, Clinical Research Program for the Division of Human Genetics, Cincinnati Children's Hospital

As patients transition from clinical research to routine clinical care, the role of the genetic counselor has evolved to include the coordination and continuity of health care. This session will highlight the needed education for the patient and family, and coordination among the health professionals involved in this transition.

VENDOR-SPONSORED PRESENTATIONS

Friday, September 30

11:45 AM – 12:15 PM

BOULDER ABORTION CLINIC

Termination of Pregnancy for Indications of Genetic Disorder and Fetal Abnormality in Advanced Gestations

Warren M. Hern, MD, MPH, PhD, Director, Boulder Abortion Clinic, Associate Clinical Professor, Department of Obstetrics and Gynecology, University of Colorado Denver Health Sciences Center

The diagnostic categories of fetal anomalies and genetic disorders for patients seen over a period of 35 years will be presented. The components of clinical care for patients seeking this service will be presented including preoperative evaluation, protocol for management of patients in different stages of pregnancy, operative techniques, postoperative management and evaluation, and procedures for grief support.

12:30 PM – 1:00 PM

natera®
Conceive. Deliver.

22q: Prenatal Clues and Commercial Data Review

Donna M. McDonald-McGinn, MS, LCGC, Chief, Section of Genetic Counseling, Director, 22q and You Center, Associate Director, Clinical Genetics Center, The Children's Hospital of Philadelphia; Libby Valenti, MS, CGC, Medical Science Liaison Manager, Natera

22q11.2 deletion syndrome has become a part of routine prenatal screening for many women through Non-Invasive Prenatal Testing (NIPT). This presentation will review prenatal clues such as ultrasound findings associated with 22q. Natera will also present the commercial experience with NIPT for 22q, including recent data.

1:15 PM - 1:45 PM

FACE2GENE

FACE2GENE: Smart Phenotyping. Better Genetics. Best Practices from Clinic to Lab.

Alyssa Blesson, MCG, LGC, Nemours/ Alfred I. duPont Hospital for Children
Sarah Savage, MS, CGC

FDNA invites you to join us to learn more about the FACE2GENE Suite. See a real case review to discover how smart phenotyping facilitates comprehensive and precise genetic evaluations.

AEConnect

Located in the Exhibitor Suite, Exhibit Hall 4AB
Open Wednesday – Friday during Exhibitor Suite hours

AEConnect is designed to help you network with your professional community. While in the Exhibitor Suite, stop by to view available job postings, learn more about our social media efforts, engage with NSGC's Special Interest Groups, take in a sponsored presentation in the Vendor Theater, and meet up with colleagues and friends.

NSGC THANKS OUR SPONSORS

NSGC Year-Round Premier Sponsors

PLATINUM

Ambry Genetics®

Quest Diagnostics™

GOLD

Asuragen®

INVITAE

AEC Sponsors

GOLD

INVITAE

myriad® WHEN DECISIONS MATTER

SILVER

Integrated GENETICS LabCorp Specialty Testing Group

sequenom

BRONZE

BAYLOR GENETICS READY WITH ANSWERS

BOULDER ABORTION CLINIC

Counsyl

GeneDx DNA DIAGNOSTIC EXPERTS

GENPATH The Premier Women's Health Laboratory

insight MEDICAL GENETICS

natera® Conceive. Deliver.

Personalis® Pioneering Genome-Guided Medicine

PREVENTION GENETICS

35TH ANNIVERSARY SPONSORS

MNG LABORATORIES

myriad® WHEN DECISIONS MATTER

EDUCATIONAL SUPPORTER

myriad® WHEN DECISIONS MATTER

NEW PATIENT RESOURCE WEBSITE

National Society of Genetic Counselors

What is a
Genetic Counselor?

How Can a Genetic Counselor
Help Me?

What Should I Expect
when Seeing a Genetic Counselor?

How Do I Find
a Genetic Counselor?

Help your patients find the answers to these questions and more on the new www.aboutgeneticcounselors.com

NSGC AWARDS AND FELLOWSHIPS

Jane Engelberg Memorial Fellowship (JEMF)

Outcomes of Genetic Counseling for Arrhythmogenic Cardiomyopathy: A Comparison of Face-to-Face and Tele-Genetic Counseling
Brittney Murray, MS, CGC

Audrey Heimler Special Project Award (AHSPA)

Development of Spanish Genetic Counseling Lexicon
Priscila D. Hodges, MS, CGC

NSGC Leadership Awards

Natalie Weissberger Paul National Achievement Award
Beth B. Crawford, MS, LCGC

Strategic Leader
Quinn Stein, MS, CGC

Strategic Leader
Jennifer M. Hoskovec, MS, CGC

Outstanding Volunteer
Colleen Caleshu, MS, LCGC

International Leader
Mercy Ygoña Laurino, MS, CGC, PhD

New Leader Award
Misha DS Rashkin, MS, CGC

Best Abstract Awards

Best Full Member Abstract Award
Adapting Evidenced Based Strategies for Effective Communication in Cancer Genetic Counseling
Robin Lee, MS, CGC

Beth Fine Kaplan Student Abstract Award
Genetic Counseling Increases Parental Knowledge and Psychological Adaptation to Turner Syndrome Diagnosis
Caitlin A. Austin

Cultural Competency Scholarship

Mike Darren Suguitan
Rebecca Wang

AEC PLANNING SUBCOMMITTEE

NSGC expresses its gratitude to these volunteers for their hard work and dedication:

Chair
Jason Flanagan, MS, CGC

Vice Chair
Renee Chard, MS, CGC

AEC Subcommittee
McKinsey Goodenberger, MS, CGC
Andrea Harbison, MS, CGC
Kelly E. Jackson, MS, CGC
Kate Lamvik Loranger, MS, CGC
Kirsty McWalter, MS, CGC
Rachel Mills, MS, CGC
Ana Morales, MS, CGC
Lauren P. Morgenroth, MS, CGC
Emily Smith, MS, CGC

Abstract Workgroup Chair
Beverly Yashar, PhD, MS, CGC

Abstract Workgroup Vice Chair
Tracey L. Grant, MS

Abstract Workgroup
Sharon Aufox, MS, CGC
Tanya Megerian Bardakjian, MS, CGC
Katie L. Berrier, MS, CGC
Courtney Berrios, MSc, ScM, CGC
Meg Bradbury, MS, CGC, MSHS
Kari Haag Branham, MS, CGC
Deanna Alexis Carere, ScD, CGC, CCGC
Kathleen Collins Ruff, MS, LGC
Julie Bars Culver, MS, LCGC, CCRP
Martha Dudek, MS, LCGC
Kelly M. East, MS, CGC
Altovise T. Ewing, PhD
Kristi Koch Fitzgerald, MS, CGC
Sara Fitzgerald-Butt, MS, CGC, LGC
Stephanie Gandomi, MS, CGC, LGC
Erynn Gordon, MS, CGC
Yue Guan, ScM, PhD, CGC
Carrie Guy, MS, CGC
Stephanie Harris, MS, CGC
Jodie Ingles, GDGC, PhD
Angela Inglis, MSc, CGC, CCGC
Emily James, MS, CGC
Yelena Kemel, MS, ScM, CGC
Devon Lamb Thrush, MS, CGC
Dawn Alyssia Laney, MS, CGC, CCRC
Elizabeth A. Lutz, MS, CGC
Erin M. Miller, MS, CGC
Sarah Jane Noblin, MS, CGC
Emily Partack, MS, CGC
Jennifer Pickard Brzosowicz, MS, CGC
Irene Rainville, MS, PhD, LGC
Victoria M. Raymond, MS, CGC, CCRP
Catherine Reiser, MS, CGC
Thereasa Rich, MS, CGC
Eric Rosenthal, PhD, ScM, LGC
Taylor J. Sale, MS, MA, MEd, LCGC
Sarah Scollon, MS, CGC
Kate P. Shane-Carson, MS, CGC, LGC
Kayla M. Sheets, MS, LGC
Sheila Solomon, MS, CGC
Michelle N. Strecker, MS, LCGC
Christopher Tan, MS, CGC
Elizabeth Ulm, MS, CGC
Karen Wain, MS, CGC
Jody Wallace, MS, CGC
Susan Walther, MS, CGC
Chani Wiesman, MS, CGC
Elisabeth Wood, MS, CGC

Education Committee Chair
Emily Edelman, MS, CGC

Education Committee Vice Chair
Colleen Caleshu, MS, CGC

Education Committee Board Liaison
Kaylene Ready, MS, CGC

NETWORKING ACTIVITIES AND BUSINESS MEETINGS

NSGC Special Interest Group (SIG) Fair

Wednesday, September 28
2:00 PM – 2:30 PM
Room 615 - 617

All AEC attendees are invited to the NSGC SIG Fair to meet with SIG leaders and to learn more about current SIG projects and how you can become involved.

First Time Attendees

AEC 101: Welcome to the Emerald City
Wednesday, September 28
2:00 PM – 3:15 PM
Room 618 - 620

Are you a first-time AEC attendee? Make your way to this event to network with other new attendees and learn about the AEC. There will also be a special SIG fair just for first-time attendees and new NSGC members. Meet with SIG leaders at this event and learn more about what NSGC's SIGs have to offer.

Welcome Reception

Wednesday, September 28
6:00 PM – 8:30 PM
Exhibit Hall 4AB

Make new contacts and greet your friends as you preview the vendors and their services in the Exhibitor Suite. Join your colleagues for this special kickoff to the AEC. Light hors d'oeuvres and a cash bar will be available.

State of the Society Address

Thursday, September 29
9:30 AM – 10:15 AM
Ballroom 6ABC

Join President Jehannine Austin, MSc, PhD, CGC, CCGC, as she provides an overview of NSGC activities and accomplishments over the past year, reviews NSGC's advocacy efforts and strategic initiatives and shares highlights from 2016.

Genome Magazine's Code Talker Award

Thursday, September 29
5:00 PM - 5:30 PM
Room 6ABC

Join *Genome Magazine* as we honor genetic counselors and announce the first winner of the Code Talker Award essay contest. Three finalists will be honored by the essayists who nominated them–sharing their emotional stories of what great care looks like from the lens of the patient. Bring your tissues!

Presented by:

Genome

Sponsored by:

INVITAE

AEC 35th Anniversary Reception

Thursday, September 29
5:30 PM – 7:45 PM
Exhibit Hall 4AB

Head to the Exhibitor Suite to celebrate the 35th Anniversary of the AEC! Join NSGC for this very special reception as we honor and demonstrate our appreciation for all genetic counselors and celebrate the history and future of the AEC and the genetic counseling profession. A hosted bar (two drink tickets per attendee) will be available.

Sponsored by:

MNG LABORATORIES

myriad WHEN DECISIONS MATTER

ABGC Annual Business Meeting

Friday, September 30
1:45 PM – 2:15 PM
Ballroom 6ABC

ACGC Presentation

Friday, September 30
2:15 PM – 2:45 PM
Ballroom 6ABC

Incoming Presidential Address

Saturday, October 1
9:30 AM – 10:00 AM
Ballroom 6ABC

Welcome NSGC President-Elect Mary Freivogel, MS, CGC, as she introduces herself to NSGC members and outlines her vision for NSGC and the genetic counseling profession in 2017.

Meals and Refreshments

Continental breakfast will be served on Wednesday in the Lobby of Ballroom 6ABC from 7:00 AM - 8:00 AM and on Thursday and Friday in the Exhibitor Suite, Exhibit Hall 4AB, from 7:00 AM - 8:00 AM and on Saturday in the lobby of Ballroom 6ABC from 7:00 AM – 8:00 AM.

Refreshment Breaks

Thursday, September 29
10:15 AM – 10:30 AM
3:00 PM – 3:15 PM

Friday, September 30
9:30 AM – 9:45 AM
3:00 PM – 3:15 PM

Saturday, October 1
10:00 AM – 10:15 AM

Join Us at the Booths Below for a Special Treat

Wednesday, September 28
6:00 PM - 8:30 PM
Myriad – Booth 601
Invitae – Booth 101
GenPath Women's Health – Booth 903

Thursday, September 29
7:00 AM - 8:00 AM
Invitae – Booth 101
Myriad – Booth 601

Thursday, September 29
5:00 PM - 7:45 PM
Myriad – Booth 601
Invitae – Booth 101
GeneDx – Booth 803

Friday, September 30
7:00 AM - 8:00 AM
Invitae – Booth 101
Myriad – Booth 601

Friday, September 30
11:15 AM - 3:00 PM
Myriad – Booth 601
Invitae – Booth 101
Insight Medical Genetics – Booth 801

NETWORKING ACTIVITIES AND BUSINESS MEETINGS

NSGC Q&A

Members of the NSGC leadership will be at specific locations during the conference to talk with members and answer questions. Stop by and share your thoughts!

Thursday, September 29
5:15 PM – 6:15 PM
AEConnect area in Exhibitor Suite

Friday, September 30
11:30 AM – 12:00 PM
AEConnect area in Exhibitor Suite

Saturday, September 30
7:15 AM – 7:45 AM
Registration Desk

Mentor Program Meet-Up

Have you ever considered joining the Mentor Program, but wanted to learn more? Are you in the Mentor Program, but haven't found your mentor match? Have you always wanted to meet your mentor match in person? Come join us for this very special Mentor Program Meet-Up event inside the AEConnect on Wednesday, September 28 from 6:30 PM – 7:30 PM.

SIG Presentations within the AEConnect

Engage with SIG leadership in the AEConnect at the following times:

Thursday, September 29	
5:00PM - 5:30PM	Prenatal SIG
5:30PM - 6:00PM	Pediatric Clinical SIG
6:00PM - 6:30PM	International SIG
6:30PM - 7:00PM	Neurogenetics SIG
Friday, September 30	
11:30AM - 12:00PM	Psychiatric SIG
12:00PM - 12:30PM	Metabolism/LSD SIG
12:30PM - 1:00PM	Education SIG
1:00PM - 1:30PM	Health IT SIG
1:30PM - 2:00PM	Cardiovascular SIG
2:00PM - 2:30PM	Student/New Member SIG
2:30PM - 3:00PM	Industry SIG

EXHIBITOR DIRECTORY BY COMPANY NAME

(as of September 6, 2016)

EXHIBITOR SUITE MAP



EXHIBITOR INDEX

23andMe
Booth 210
899 W. Evelyn Avenue
Mountain View, CA 94041
Phone: 650.938.6300
23andme.com

Founded in 2006, 23andMe is the first and only genetic service available directly to consumers that offers reports that meet FDA standards for being scientifically and clinically valid.

AbortionClinics.org/AAF, Inc.
Booth 211
1002 West Mission Ave
Bellevue, NE 68005
Phone: 402.291.4797
Fax: 402.291.4643
acconebraska@gmail.com
abortionclinics.org

We have been providing abortion services for more than 30 years. We specialize in 3rd trimester terminations for fetal anomalies.

Affymetrix, part of Thermo Fisher Scientific
Booth 303
3420 Central Expressway
Santa Clara, CA 95051
Phone: 408.731.5000
Fax: 408.731.5646
sales@affymetrix.com
affymetrix.com

Affymetrix, part of Thermo Fisher Scientific, is your partner for pediatric genetics. We offer the only FDA-cleared whole-genome diagnostic test, CytoScan® Dx Assay, proven to aid in the diagnosis of developmental delay and intellectual disabilities.

Alexion Pharmaceuticals
Booth 910
100 College Street
New Haven, CT
Phone: 203.272.2596 (ALXN)
Fax: 203.271.8198
alexion.com

Alexion is a global biopharmaceutical company focused on developing life-transforming therapies for patients with rare disorders. Alexion developed the first and only approved complement inhibitor to treat patients with PNH and aHUS. Alexion's metabolic franchise includes two enzyme replacement therapies for patients with ultra-rare disorders, HPP and LAL-D.

Allele Diagnostics
Booth 218
44 W 6th Avenue, Suite 202
Spokane, WA 99204
Phone: 844.255.3532
Fax: 509.232.5779
info@allelediagnostics.com
allelediagnostics.com

Allele Diagnostics is a genetic company focused on providing high-quality testing and reporting services. Our specialty is rapid microarray, but we offer a unique test menu that is focused on pediatric and prenatal patients.

Alpha-1 Foundation
Booth 224
3300 Ponce de Leon Boulevard
Coral Gables, FL 33134
Phone: 877.228.7321
info@alphaone.org
www.alpha1.org

The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide.

Ambry Genetics
Booth 316
15 Argonaut
Aliso Viejo, CA 92656
Phone: 949.900.5500
Fax: 949.900.5501
info@ambrygen.com
ambrygen.com

Ambry is a genetics-based healthcare company that is dedicated to open scientific exchange so we can work together to understand all human disease faster and save millions of lives.

American Board of Genetic Counseling
Booth 618
PO Box 14216
Lenexa, KS 66285
Phone: 913.222.8661
Fax: 913.222.8606
info@abgc.net
abgc.net

The American Board of Genetic Counseling (ABGC) is the credentialing organization for the genetic counseling profession in the U.S. and Canada. ABGC certifies and recertifies qualified genetic counseling professionals and promotes growth and development of the profession.

American Thrombosis & Hemostasis Network (ATHN)
Booth 205
72 Treasure Lane
Riverwoods, IL 60015
Phone: 800.360.2846
Fax: 847.572.0967
info@athn.org
athn.org

The American Thrombosis and Hemostasis Network (ATHN) is a non-profit organization committed to advancing and improving care for individuals affected by bleeding and thrombotic disorders. ATHN manages a national database of patient health data that can be used to improve care and support vital research.

ARUP Laboratories
Booth 201
500 Chipeta Way
Salt Lake City, UT 84108
Phone: 801.583.2787
Fax: 801.584.5209
alyson.willerton@aruplab.com
aruplab.com

ARUP, a nonprofit enterprise of the University of Utah, has a full-service genetics laboratory offering testing in maternal serum screening and molecular, cyto, and biochemical genetics, with experience in sequencing, MLPA, FISH, microarray, and biochemical assays.

AstraZeneca
Booth 523
101 Orchard Ridge Drive
Gaitherburgh, MD 20878
Phone: 301.398.0000
joe.conyer@astrazeneca.com
astrazeneca-us.com

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – respiratory and autoimmunity, cardiovascular and metabolic diseases, and oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

EXHIBITOR INDEX

Asuragen
Booth 705
2150 Woodward Street, Suite 100
Austin, TX 78744
Phone: 512.681.5200
Fax: 512.681.5201
asuragen@asuragen.com
asuragen.com

The Asuragen Genetics portfolio delivers innovative solutions that are designed to solve unmet testing needs and empower researchers to advance the understanding of inherited disorders, from ALS to Fragile X syndrome.

Baby's First Test
Booth 430
4301 Connecticut Avenue NW, Suite 404
Washington, DC 20008
Phone: 202.966.5557
info@babysfirsttest.org
babysfirsttest.org

Baby's First Test houses the nation's newborn screening clearinghouse. As the clearinghouse, Baby's First Test connects parents and healthcare providers with information and resources on newborn screening at the local, state, and national levels.

Basser Center for BRCA
Booth 608
3400 Civic Center Boulevard
3 West Pavilion
Philadelphia, PA 19104
Phone: 215.662.2748
Fax: 215.349.5314
basserinfo@uphs.upenn.edu
basser.org

The Basser Center for BRCA at Penn Medicine's Abramson Cancer Center is the first comprehensive center solely devoted to funding research, educating providers and patients, and advancing care for individuals with BRCA gene mutations.

Baylor Genetics
Booth 401
2450 Holcombe Boulevard, Suite O-100
Houston, Texas 77021
Phone: 713.798.6555
genetictest@bmgl.com
bmgl.com

Baylor Genetics Laboratories offer a broad range of diagnostic genetics tests. We provide state of the art testing including, DNA diagnostics, prenatal testing, chromosomal microarray analysis, whole exome sequencing, biochemical genetics, Mitochondrial disease panels and metabolic testing as well as cancer testing.

BioMarin Pharmaceutical Inc.
Booth 426
105 Digital Drive
Novato, CA 94949
Phone: 415.506.6700
Fax: 415.382.7889
biomarin.com

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. Approved products include the first and only medications for PKU and LEMS, and the first and only enzyme replacement therapies for MPS I, MPS VI and Morquio A syndrome.

Blueprint Genetics
Booth 429
953 Indiana Street
San Francisco, CA 94107
Phone: 650.452.9340
jessica.kim@blueprintgenetics.com
blueprintgenetics.com

Blueprint Genetics is changing diagnostics by providing accessible and actionable genetic knowledge. Our mission is to support healthcare professionals in providing the best care for patients with rare inherited diseases. We provide fast, affordable and comprehensive genetic diagnostics.

Boulder Abortion Clinic, PC
Booth 510
1130 Alpine Avenue
Boulder, CO 80304
Phone: 303.447.1361
Fax: 303.447.0020
drhern.com

Boulder Abortion Clinic's Dr. Warren Hern provides services to select patients beyond 30 menstrual weeks for fetal anomaly and maternal indications. Assistance with genetic testing and grievance services is available.

Bright Pink
Booth 729
670 N. Clark Street
Chicago, IL 60610
Phone: 312.787.4412
brightpink@brightpink.org
brightpink.org

Bright Pink is a national non-profit on a mission to prevent breast and ovarian cancer by inspiring proactive behavior change among young women and their healthcare providers.

CancerGene Connect
Booth 307
1701 N. Market Street, Suite 435
Dallas, TX 75202
Phone: 214.862.1957
Fax: 972.455.8638
info@cagene.com
cagene.com

CancerGene Connect© is a cloud-based genetic risk assessment and pedigree tool originally developed by UT Southwestern. It remotely gathers patient history, runs risk assessment models, draws pedigrees, generates patient reports, and creates a comprehensive database.

CancerIQ
Booth 628
222 W Merchandise Mart Plaza #1230
Chicago IL 60654
Phone: 888.802.2623
adowning@canceriq.com
canceriq.com

CancerIQ makes it easy for practices to offer genetic cancer risk assessment programming to every patient that walks through the door. Our solutions help genetic counselors to save time, enrich the face-to-face counseling experience, and improve patient outcomes over time. We enable any busy healthcare system to start, run, and grow a highly impactful cancer genetics program at lower costs.

CBR, from AMAG Pharmaceuticals Inc.
Booth 301
1100 Winter Street
Waltham, MA 02451
Phone: 617.498.3300
Fax: 617.649.1632
contactus@amagpharma.com
www.amagpharma.com

At CBR, our mission is to enable more breakthrough medical treatments for more families. We do that by significantly advancing the real-life clinical applications of newborn stem cells; searching to uncover potential through clinical trials; and aspiring to perfection in collection, processing and storage of stem cells.

EXHIBITOR INDEX

Cedar River Clinics

Booth 112

263 Rainier Ave S
Renton, WA 98057
Phone: 800.572.4223
Fax: 425.255.0262
friends@CedarRiverClinics.org
www.CedarRiverClinics.org

Cedar River Clinics offers compassionate abortion care to 26 weeks with special fetal indication services. We are happy to assist clients and their families with transportation, local lodging and funding resources.

CdLS Foundation

Booth 1000

302 West Main Street #100
Avon, CT 06001
Phone: 800.753.2357
Fax: 860.676.8337
info@CdLSusa.org
cdlsusa.org

The CdLS Foundation is a family support organization that exists to ensure early and accurate diagnosis, promote research into causes and manifestations of the syndrome, and help people with CdLS make informed decisions.

Children's National Fetal Medicine Institute

Booth 921

111 Michigan Avenue NW
Washington, DC 20010
Phone: 202.476.7409
fetalmedicine@childrensnational.org
ChildrensNational.org/Fetal

The Children's National Fetal Medicine Institute provides advanced and comprehensive care for unborn babies with known or suspected medical conditions in a compassionate and supportive environment, offering pregnant families advanced fetal diagnostics and treatment.

Clinical Genome Resource (ClinGen)

Booth 900

120 Hamm Drive
Lewisburg, PA 17837
clingen@clinicalgenome.org
clinicalgenome.org

The Clinical Genome Resource (ClinGen) is an NIH-funded effort dedicated to building an authoritative central resource that defines the clinical relevance of genes and variants for use in precision medicine and research.

Clovis Oncology

Booth 511

We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.

Color Genomics

Booth 207

1801 Murchison Drive #128
Burlingame, CA 94010
Phone: 844.362.6567
providers@getcolor.com
getcolor.com

Color Genomics' mission is to democratize access to genetic information. For $249, Color provides a clinical-grade physician ordered test that analyzes 30-genes to help women and men learn their risk for the most common hereditary cancers.

EXHIBITOR INDEX

CombiMatrix
Booth 517

300 Goddard, Suite 100
Irvine, CA 92618
Phone: 949.753.0624
marketing@combimatrix.com
combimatrix.com

CombiMatrix is a clinical diagnostic laboratory specializing in cytogenomic testing for prenatal diagnosis, miscarriage analysis, preimplantation genetic screening and pediatric developmental disorders.

Connective Tissue Gene Tests (CTGT)
Booth 309

6575 Snowdrift Road, Suite 106
Allentown, PA 180106
Phone: 484.244.2900
Fax: 484.244.2904
inquiries@ctgt.net
ctgt.net

CTGT specializes in prenatal and postnatal molecular diagnostics for a variety of inherited genetic disorders offering over 1,500 NGS, Sanger and Deletion/Duplication tests. CTGT provides high test sensitivity, rapid turnaround times and superior customer service.

Counsyl
Booth 629

180 Kimball Way
South San Francisco, CA 94080
Phone: 888.268.6795
info@counsyl.com
counsyl.com

Counsyl is a DNA testing and genetic counseling service. We strive to put patients first, put clinicians in control, and put costs in their place. Counsyl has screened more than 600,000 patients and served more than 10,000 health care professionals.

Emory Genetics Laboratory
Booth 408

2165 North Decatur Road
Decatur, GA 30033
Phone: 404.778.8499
Fax: 404.778.8559
egl.marketing@emory.edu
geneticslab.emory.edu

Emory Genetics Laboratory offers a combined 1,100 molecular, biochemical, and cytogenetic tests under one roof and custom testing for all medically relevant genes, for domestic and international clients.

FDNA
Booth 427

745 Atlantic Avenue 8th Floor
Boston, MA 02111
Phone: 617.412.7000
jeff@fdna.com
Face2Gene.com

FDNA is maker of Face2Gene, a suite of phenotyping apps that facilitates comprehensive and precise genetic evaluations.

FORCE: Facing Our Risk of Cancer Empowered
Booth 620

16057 Tampa Palms Boulevard W, #373
Tampa, FL
Phone: 866.288.7475 (RISK)
Fax: 954.827.2200
info@facingourrisk.org
facingourrisk.org

FORCE is a national nonprofit organization dedicated to people affected by hereditary breast, ovarian and related cancers. Our programs provide support, education, advocacy and research to help those facing hereditary cancers make informed decisions.

EXHIBITOR INDEX

Fulgent Diagnostics
Booth 206
4978 Santa Anita Avenue, Suite 205
Temple City, CA 91780
Phone: 626.350.0537
Fax: 626.454.1667
info@fulgentdiagnostics.com
fulgentdiagnostics.com

Fulgent Diagnostics has a broad and unique portfolio of genetic tests, including over 18,000 single gene tests, over 190 preset panels, rearrangement testing, clinical exome/trios, whole exome/trios, whole genome and our All-in-One reflex test.

Geisinger Health System
Booth 1001
100 N. Academy Avenue
Danville, PA 17821
Phone: 570.214.6918
gbmccluskey@geisinger.edu
geisinger.org

Geisinger is one of the nation's largest health service organizations, serving 3 million residents in Pennsylvania and New Jersey. We are comprised of 1,600 employed physicians, 12 hospitals, two research centers and a 510,000-member health plan.

GeneDx
Booth 803
207 Perry Parkway
Gaithersburg, MD 20877
Phone: 301.519.2100
GeneDx@GeneDx.com
www.GeneDx.com

GeneDx, an OPKO Health Company, offers sequencing and deletion/duplication testing for inherited cardiac disorders, mitochondrial disorders, neurological disorders, cancer disorders, and other rare genetic disorders. Whole exome sequencing, microarray-based testing, targeted variant testing, and prenatal diagnostic services are also available.

Genesis Genetics
Booth 825
705 S. Main Street
Plymouth, MI 48170
Phone: 313.579.9650
Fax: 313.544.4006
info@genesisgenetics.org
genesisgenetics.org

At Genesis Genetics, we are invested in reproductive genetic health. We develop new technologies to harness that power of the genome and to help build healthy families.

GeneTests.org
Booth 907
481 Edward H Ross Drive
Elmwood Park, NJ 07407
Phone: 208.729.1204
genetests@genetests.org
GeneTests.org

GeneTests is an online medical genetics information resource with capability to search by test, disorder, or gene. GeneTests searches retrieve links to GeneReviews™ chapters, other online resources and genetic testing information.

Genetic Support Foundation
Booth 829
1800 Cooper Point Road SW #14
Olympia, WA 98502
Phone: 844.743.6384
contact@geneticsupportfoundation.org
geneticsupportfoundation.org

We are a nonprofit whose mission involves improving healthcare by providing objective genetic information to patients, providers, and healthcare organizations, supporting those in need of genetic services and facilitating the adoption of best genetic practices.

Genome Magazine
Booth 913
6900 Dallas Parkway Suite 200
Plano, TX 75024
Phone: 972.905.2920
tstammen@genomemag.com
genomemag.com

Genome Magazine explores the world of personalized medicine and the genomic revolution that makes it possible, empowering readers to make informed health decisions that will help them live better and longer.

Genomind, Inc.
Booth 801
2200 Renaissance Boulevard, Suite 100
King of Prussia, PA 19406
Phone: 877.895.8658
Fax: 844.364.5850
customerservice@genomind.com
genomind.com

Genomind is a personalized medicine company bringing innovation to mental healthcare through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology who specialize in pharmacogenetic laboratory testing for psychiatry.

GenPath Women's Health
Booth 903
481 Edward H. Ross Drive
Elmwood Park, NJ 07407
Phone: 800.633.4522
info@GenPath.com
www.GenPath.com

GenPath Women's Health, a division of BioReference Laboratories, an OPKO Company, specializes in the diagnostic needs of MFM and Ob-Gyn, including prenatal/maternal risk assessment, carrier testing, prenatal diagnosis, pregnancy thrombophilia and infectious diseases. GenPath Women's Health is a sister division of GeneDx, an established leader in genetic testing for rare inherited diseases.

Greenwood Genetic Center
Booth 616
106 Gregor Mendel Circle
Greenwood, SC 29646
Phone: 800.473.9411
Fax: 864.941.8141
GGC.org

The Greenwood Genetic Center is a nonprofit institute organized to provide clinical genetic services, diagnostic laboratory testing, educational resources and research in the field of medical genetics. Our laboratory offers biochemical, cytogenetic and molecular testing.

Harmony Prenatal Test
Booth 826
9115 Hague Road
Indianapolis, IN 46250
Phone: 317.521.7615
Fax: 317.565.4089
lisa.glavan@roche.com
harmonytestusa.com

Harmony is a non-invasive prenatal test evaluating the risk of Trisomy 21, 18 and 13 as early as 10 weeks in pregnant women of any age or risk category. The Harmony test is developed by Ariosa Diagnostics. Ariosa Diagnostics is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).

Illumina, Inc.
Booth 609
5200 Illumina Way
San Diego, CA 92122
Phone: 858.202.4500
Fax: 858.202.4766
info@illumina.com
illumina.com

Illumina is improving human health by unlocking the power of the genome. Our genomic solutions are used for applications in oncology, reproductive health, and genetic disease research.

EXHIBITOR INDEX

Insight Medical Genetics
Booth 810

680 N Lake Shore Drive, Suite 1230
Chicago, IL 60611
Phone: 312.981.4400
Fax: 312.981.4404
IMGLab@insightmedicalgenetics.com
insightmedicalgenetics.com

As an integrated clinical and laboratory genetics company, Insight Medical Genetics offers a spectrum of pre and postnatal counseling and lab services to providers across the country including results interpretation by licensed board-certified genetic counselors.

Integrated Genetics
Booth 300

3400 Computer Drive
Westborough, MA 01581
Phone: 800.848.4436
integratedgenetics.com

Integrated Genetics is a leading provider of reproductive genetic testing services driven by its commitment to physicians and their patients. With years of testing expertise utilizing sophisticated technologies, Integrated Genetics spans the continuum of care, ranging from maternal serum screening and prenatal diagnostics to carrier screening and postnatal testing services.

Invitae
Booth 100

458 Brannan Street
San Francisco, CA 94107
Phone: 213.300.5464
leslie.spillman@invitae.com
invitae.com

Invitae offers high-quality, affordable genetic testing for oncology, cardiology, neurology, pediatrics, and more. Join us in our mission is to bring genetic information into mainstream medical practice to improve healthcare for everyone.

Kaiser Genetics - Northern California
Booth 606

Jazmine.Jung@kp.org
genetics.kp.org

Practice what you believe, practice at Kaiser Permanente! Kaiser Genetics is the employer of choice for over 70 genetic counselors in Northern California.

LAL-D Aware made possible by GenoPheno
Booth 827

LAL-D Aware is a patient support resource for families impacted by lysosomal acid lipase deficiency. Previously LAL Solace, we changed our name to LAL-D Aware because disease intervention advances give cause for optimism and hope.

Mayo Medical Laboratories
Booth 508

3050 Superior Drive NW
Rochester, MN 55905
Phone: 800.533.1710
mml@mayo.edu
MayoMedicalLaboratories.com

Mayo Medical Laboratories is a global reference laboratory operating within Mayo Clinic's Department of Laboratory Medicine and Pathology. Our comprehensive test menu includes biochemical and molecular assays for screening, diagnosing, and monitoring lysosomal storage disorders in both children and adults.

MNG Laboratories
Booth 529

5424 Glenridge Drive NE
Atlanta, GA 30342
Phone: 678.225.0222
Fax: 678.225.0212
quickresponse@mnglabs.com
mnglabs.com

MNG provides expert diagnostics through biochemical testing, metabolic testing and Next Generation Sequencing. Our panels are cost effective and comprehensive, particularly for cellular energetics, muscular dystrophies and epilepsy.

MotherToBaby Pregnancy Studies
Booth 304

9500 Gilman Drive, MC 0828
La Jolla, CA 92093
Phone: 877.311.8972
Fax: 858.246.1710
mothertobaby@ucsd.edu
mothertobaby.org

MotherToBaby, a non-profit service of the Organization of Teratology Information Specialists (OTIS), is dedicated to providing evidence-based information to mothers, health care professionals, and the general public about medications and other exposures during pregnancy and while breastfeeding. MotherToBaby's research division is conducting an observational research study to evaluate the effects to the fetus from asthma and the safety of medications and vaccinations used during pregnancy.

Mount Sinai Genetic Testing Laboratory
Booth 111

1428 Madison Avenue, Atran Building 2
New York, NY 10029
Phone: 212.241.7518
Fax: 212.241.0139
dave.dubin@mssm.edu
icahn.mssm.edu/genetictesting

Mount Sinai offers high-quality genetic testing and diagnostic, therapeutic and counseling services for patients with hereditary cancer, genetic disorders and birth defects. Our latest carrier screening test accurately screens for 281 genetic diseases.

Myriad Genetic Laboratories
Booth 601

320 Wakara Way
Salt Lake City, UT 84108
Phone: 801.584.3600
cscomments@myriad.com
myriad.com

Myriad Genetics is a leading molecular and companion diagnostics company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative products that assess a person's risk of developing disease, aid in a timely and accurate diagnosis, determine the risk of disease progression and recurrence and guide personalized treatment decisions.

Natera
Booth 417

201 Industrial Rd
San Carlos, CA 94070
Phone: 650.249.9090
jaliamus@natera.com
www.natera.com

Natera® is a rapidly growing genetic testing and diagnostics company with proprietary bioinformatics and molecular technology. Natera's team of PhDs and engineers is dedicated to refining novel molecular genome assays and complex statistical algorithms to determine the likelihood of a wide range of serious genetic conditions with best-in-class accuracy and coverage.

National Library of Medicine
Booth 521

EXHIBITOR INDEX

NextGxDx
Booth 711

810 Crescent Centre Drive
Franklin, TN 37067
Phone: 615.861.2641
mhertik@nextgxdx.com
nextgxdx.com

NextGxDx improves genetic test ordering for the GC community with two solutions. GeneSource is a comprehensive and easy-to- use tool to search and compare genetic tests. GeneConnect provides advanced ordering/reporting tools to support genetic testing UM efforts.

NIH Genetic Testing Registry/MedGen/ClinVar
Booth 509

9000 Rockville Pike
Bethesda, Maryland 20892
gtr@ncbi.nlm.nih.gov
ncbi.nlm.nih.gov/guide/genetics-medicine

12,200 conditions, 4,300 genes, 157,000 variants and 35,000 genetic tests in 100 square feet. See what's new with NCBI's Medical Genetics resources: ClinVar, GTR and MedGen.

Norton & Elaine Sarnoff Center for Jewish Genetics
Booth 630

30 S. Wells, 216-600
Chicago, IL 60606
Phone: 312.357.4988
jewishgenetics@jewishgenetics.org
jewishgenetics.org

The Sarnoff Center for Jewish Genetics provides resources for the Jewish community and healthcare professionals about recessive disorders, hereditary cancers, and other genetic health issues common among Jewish persons and in interfaith families.

NTD Labs
Booth 402

80 Ruland Road
Melville, NY 11747
Phone: 855.754.5221
ntdlabs.com

NTD Labs, an innovative leader in prenatal screening, provides accurate and timely information to healthcare providers and expectant parents. We achieve this through our unwavering dedication to research, exceptional customer service and continuous improvement. With over four decades of prenatal screening experience in the maternal fetal health industry, NTD Labs was the first to introduce ONTD, Down Syndrome, Early Onset Preeclampsia and first trimester AFP screening.

Oregon Reproductive Medicine
Booth 915

808 SW 15th Avenue
Portland, OR 97205
Phone: 503.290.1537
hello@oregonreproductivemedicine.com
OregonReproductiveMedicine.com

Oregon Reproductive Medicine (ORM) is a world-class fertility center that is passionately committed to helping people grow their families. ORM offers individuals and couples the most cutting-edge technology in vitro fertilization (IVF) and genomic medicine available.

Partners Personalized Medicine Lab for Molecular Medicine
Booth 519

65 Landsdowne Street
Cambridge, MA 02139
Phone: 617.768.8600
Fax: 617.525.4488
lmm@partners.org
partners.org/personalizedmedicine/lmm

The Laboratory for Molecular Medicine (LMM) is a CLIA-certified molecular diagnostic laboratory. We offer comprehensive testing services to support clinical research and clinical practice including single gene, multiple gene panel, exome and genome sequencing.

Perinatal Quality Foundation
Booth 917

Personalis, Inc.
Booth 409

1330 O'Brien Drive
Menlo Park, CA 94025
Phone: 650.752.1300
Fax: 650.752.1301
info@personalis.com
personalis.com

Personalis, Inc. provides clinicians and researchers advanced genome-scale sequencing and interpretation services for inherited genetic disease and cancer. The company's clinical laboratory is CLIA licensed and CAP accredited.

Pfizer
Booth 528

335 E. 42nd Street
New York, NY 10017
Phone: 949.482.9925
Teresa.rousseau@pfizer.com

Pfizer Rare Diseases - providing biological therapies for rare and ultra rare diseases.

Phenogen Sciences, Inc.
Booth 109

9115 Harris Corners Parkway, Suite 320
Charlotte, NC 28269
Phone: 877.992.7382
Fax: 704.926.5707
customersupport@phgns.com
www.brevagenplus.com

BREVAGenplus™ is the first clinically validated, genetic-based risk assessment test for sporadic (non-hereditary) breast cancer. BREVAGenplus™ combines clinical risk factors with genetic markers for a more accurate assessment of a woman's 5-year and lifetime risk.

PreventionGenetics
Booth 701

3800 South Business Park Avenue
Marshfield, WI 54449
Phone: 715.387.0484
Fax: 715.384.3661
clinicaldnatesting@preventiongenetics.com
preventiongenetics.com

PreventionGenetics is a leader in providing comprehensive clinical DNA testing testing offering sequencing for over 1,600 genes and deletion/duplication testing for over 1,500 genes. PreventionGenetics is CAP/CLIA accredited.

Proband - The Children's Hospital of Philadelphia
Booth 823

3535 Market Street, Suite 1024
Philadelphia, PA 19104
Phone: 267.426.7522
Fax: 215.590.5245
vitod@email.chop.edu
probandapp.com

Proband is an iPad® app that captures a patient's genetic pedigree during the clinical encounter. Proband Connect synchronizes pedigrees across multiple devices and lets you securely share them with other users, and can integrate with third-party applications.

Progenity
Booth 811

4330 La Jolla Village Drive, Suite 200
San Diego, CA 92122
Phone: 855.293.2639
Fax: 760.268.0771
client.services@progenity.com
progenity.com

At Progenity, we partner with clinicians to offer advanced diagnostic tests that help patients and their families Prepare for Life. Progenity's genetic counselors work as part of the healthcare team.

EXHIBITOR INDEX

Progeny Genetics
Booth 326

Providence Health & Services
Booth 530

2201 Lind Avenue SW
Renton, WA 98057
Phone: 877.5646.747 (JOIN.PHS)
jobs@providence.org
providenceiscalling.jobs

Providence Health & Services is the third-largest not-for-profit health system in the country, serving five western states. Our vision is to create healthier communities together, with special focus on the poor and vulnerable.

Quest Diagnostics
Booth 817

3 Giralda Farms
Madison, NJ 07940
Phone: 973.520.2793
www.questdiagnostics.com

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, offers a comprehensive Genetics Testing menu, including Prenatal and Neonatal, Oncology, Neurology and Endocrinology. We empower health with diagnostic insights.

Recordati Rare Diseases Inc.
Booth 327

100 Corporate Drive
Lebanon NJ 08833
Phone: 908.236.0888
Fax: 908.236.0028
info@recordatirarediseases.com
recordatirarediseases.com

Recordati Rare Diseases is a biopharmaceutical company committed to providing therapies to people with rare diseases. Our team works with rare disease communities to increase awareness, improve diagnosis and ensure access to effective treatments.

Reprogenetics and Recombine
Booth 308

3 Regent Street, Suite 301
Livingston, NJ 07039
Phone: 973.727.6903
nicole@reprogenetics.com

Recombine and Reprogenetics, CooperSurgical Companies, are your partners in comprehensive and seamless reproductive genetic testing. Dedicated to providing clinically actionable expanded carrier screening, NIPS, PGS, and PGD results, Recombine and Reprogenetics are advancing the field of reproductive genetics and empowering families worldwide.

Retrophin
Booth 912

Sanofi Genzyme
Booth 400

500 Kendall Street
Cambridge, MA 02142
Phone: 617.768.6140
valery.osias@genzyme.com

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

Seattle Children's Hospital, PLUGS Program
Booth 709

4800 Sand Point Way NE
Seattle, WA 98105
Phone: 206.987.3361
plugs@seattlechildrens.org
seattlechildrenslab.org/plugs

PLUGS (Pediatric Laboratory Utilization Guidance Services) mission is to reduce test ordering errors in the U.S. and decrease the financial burden of unnecessary testing on families. PLUGS began in 2012, and has grown into a national collaboration of 60 institutions.

Sequenom, Inc.
Booth 708

3595 John Hopkins Court
San Diego, CA 92121
Phone: 877.821.7266
info@sequenom.com
sequenom.com

Sequenom, Inc. is the trusted source for genetic testing that guides reproductive health matters, providing answers that assist patients and physicians in proactively addressing informed family planning.

Sharsheret
Booth 203

1086 Teaneck Road, Suite 2G
Teaneck, NJ 07666
Phone: 866.474.2774
Fax: 201.837.5025
info@sharsheret.org
sharsheret.org

Sharsheret is a national, non-profit organization that supports Jewish women of all backgrounds, facing breast and ovarian cancer—those who are diagnosed and those at high risk.

Shire
Booth 731

300 Shire Way
Lexington, MA 02421
Phone: 617.349.0200
drafferty0@shire.com
shire.com

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We have best-in-class products available in more than 100 countries across core therapeutic areas including hematology, immunology, neuroscience, lysosomal storage disorders, gastrointestinal/internal medicine/endocrine and hereditary angioedema; a growing franchise in oncology; and an emerging, innovative pipeline in ophthalmics.

Simons VIP Connect
Booth 901

100 N. Academy Avenue; MC: 30-42
Danville, PA 17822
Phone: 855.329.5638
Fax: 570.214.7327
coordinator@simonsvipconnect.org
simonsvipconnect.org

Simons VIP is a family-support community and research initiative aimed at better understanding the medical, learning, and behavioral features of individuals with genetic changes associated with autism spectrum disorder (ASD) and developmental delay.

SimulConsult
Booth 227

27 Crafts Road
Chestnut Hill, MA 02467
Phone: 617.879.1670
Fax: 617.849.5993
info@simulconsult.com
simulconsult.com

SimulConsult provides 3 tools for genetic counselors: a personalized evidence-based list of most useful genes to test for an individual patient based on their findings; automatically-generated letters of medical necessity; and prognosis tables for all inherited disorders.

EXHIBITOR INDEX

Southwestern Women's Options

Booth 306

522 Lomas Boulevard NE
Albuquerque, NM 87102
Phone: 505.242.7512
Fax: 505.242.0540
swoadmin@covad.net
southwesternwomens.com

A clinic owned by Curtis Boyd, MD, the Albuquerque office specializes in third trimester abortion care and offers a unique Fetal Indications Program geared to the special needs of the patient and her family.

Special Angels Adoption

Booth 216

77 Russ Road
Jackson, OH 45640
Phone: 256.452.9504
Fax: 740.422.1675
jennifer@specialangelsadoption.org
specialangelsadoption.org

We are a fully licensed, 501(c)(3) non-profit, custodial adoption agency handling almost exclusively the adoptions of children with special needs. We are based in Ohio but can work with any family in the United States.

The Center for Fetal Diagnosis and Treatment at the Children's Hospital of Philadelphia

Booth 622

3401 Civic Center Boulevard
Philadelphia, PA 19104
Phone: 800.468.8376 (800.IN.UTERO)
Fax: 215.590.2447
fetalsurgery@email.chop.edu
fetalsurgery.chop.edu

Experts in in prenatal diagnosis and treatment, and home of the first specialized delivery unit exclusively for families carrying a fetus with a congenital anomaly, since 1995 we have provided care for 20,000 pregnancies.

EXHIBITOR INDEX

ThinkGenetic, Inc.
Booth 431

328 Old Lancaster Road
Sudbury, MA
Phone: 866.417.7348 x700
Fax: 978.443.0186
info@thinkgenetic.com
thinkgenetic.com

ThinkGenetic.com is a revolutionary, informational genetics website that provides a free, personalized, interactive, patient-focused roadmap for those living with a genetic disease and possible directions for those on a diagnostic odyssey.

UAB Medical Genomics Laboratory
Booth 507

720 20th Street South, Suite 330
Brimingham, AL 35294
Phone: 205.934.5562
Fax: 205.996.2929
medgenomics@uabmc.edu
genetics.uab.edu/medgenomics

The UAB Medical Genetics Labratory (MGL) provides sensitive, comprehensive, reliable and cost-effective testing to help with early and accurate diagnosis of genetic disorders. The MGL has a special focus on and expertise in all forms of the neurofibromatoses, the rasopathies and tuberous sclerosis.

UCLA Clinical Genomics Center
Booth 800

10833 Le Conte Avenue, AS-370 CHS
Los Angeles, CA 90095
Phone: 310.775.5884
Fax: 818.989.6778
scwebb@mednet.ucla.edu
pathology.ucla.edu/genomics

UCLA Clinical Genomics Center offers clinical exome sequencing (CES), genetic counseling, and expert interpretation by our Genomic Data Board. CES and our extensive menu of genetic and genomic testing for hereditary disorders, cancer diagnosis/management and other conditions are performed within our CLIA-certified, CAP-accredited Molecular Diagnostics Laboratories. Available techniques include Sanger sequencing, FISH, chromosomal microarray for postnatal and prenatal evaluation, neoplastic conditions, and targeted next gen sequencing panels for lung, colorectal, thyroid and hematologic malignancies.

UCLA Health
Booth 406

UCSF Fetal Treatment Center
Booth 222

1855 Fourth Street, 2nd Floor, A-2432
San Francisco, CA 94158
Phone: 800.RX.FETUS
Fax: 415.502.0660
fetus@surgery.ucsf.edu
fetus.ucsf.edu

The UCSF Fetal Treatment Center is a world leader in diagnosing and treating birth defects before delivery. We offer comprehensive, family-centered care in one location, from diagnosis and prenatal management through postnatal care and long-term follow-up.

Ultragenyx Pharmacuetical
Booth 114

60 Leveroni Court
Novato, CA 94949
Phone: 415.483.8800
Fax: 415.483.8810
info@ultragenyx.com
ultragenyx.com

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

Undiagnosed Diseases Network
Booth 220

10 Shattuck Street
Boston, MA 02127
Phone: 844.746.4836
Fax: 617.432.5105
UDN@hms.harvard.edu
undiagnosed.hms.harvard.edu

The Undiagnosed Diseases Network, a research project supported by the National Institutes of Health Common Fund, brings together clinical and research experts from across the country to try to solve the most challenging medical mysteries.

University of Chicago Genetic Services Laboratories
Booth 526

5841 S Maryland Avenue, MC0077
Chicago, IL 60637
Phone: 773.834.0555
Fax: 773.702.9130
ucgslabs@genetics.uchicago.edu
dnatesting.uchicago.edu

UCGSL offers cutting-edge clinical DNA diagnostic services. Our test menu includes exome sequencing, in addition to testing for a wide range of disorders including brain malformations, ataxia, epilepsy, neuromuscular disorders, hereditary cancers and endocrine disorders.

University of Washington
Booth 911

1959 NE Pacific Avenue
Seattle, WA 98195
Phone: 206.598.6429
Fax: 206.598.0304
genelab@uw.edu
depts.washington.edu/labweb/DivisionsMolDiag/MolDiagGen/index.htm

UW-OncoPlex is a multiplexed gene sequencing panel that detects mutations in tumor tissue in 194 cancer-related genes; BROCA genetic risk panel for 62 genes; Coloseq and Coloseq Tumor genetic test using NGS.

UNMC Human Genetics Laboratory
Booth 727

985440 Nebraska Medical Center
Omaha, NE 68198
Phone: 402.559.5070
Fax: 402.559.7248
humangenetics@unmc.edu
unmc.edu/geneticslab

The Human Genetics Laboratory at the University of Nebraska Medical Center (UNMC) is a full-service clinical cytogenetics and molecular genetics laboratory specializing in both constitutional (prenatal and postnatal) and cancer diagnostics for over 40 years.

EXHIBITOR INDEX

UPMC
Booth 329

600 Grant Street
Pittsburgh, PA 15219
Phone: 412.864.4254
upmc.com

A world-class health care system with over 62,000 employees, Pittsburgh-based UPMC operates more than 20 academic, community, and specialty hospitals (including four awarded MAGNET recognition), plus over 500 doctors' offices, outpatient sites, rehabilitation, retirement, and long-term care facilities. UPMC also insures over 2.9 million people through the UPMC Health Plan.

UW Medicine Center for Precision Diagnostics
Booth 428

1959 NE Pacific Street, HSB H-561
Seattle, WA 98195
Phone: 206.543.0459
Fax: 206.616.1899
cpdx@uw.edu
uwcpdx.org

The UW Medicine Center for Precision Diagnostics (CPDx) is a CLIA/CAP Accredited clinical genetic testing program comprised of the Collagen Diagnostic Laboratory, Northwest Clinical Genomics Laboratory, Clinical Flow Cytometry Laboratory, and Clinical Cytogenomics Laboratory.

Valley Children's Hospital
Booth 610

9300 Valley Children's Place
Madera, CA 93636
Phone: 559.353.7058
Fax: 559.353.7070
dyee@valleychildrens.org
valleychildrens.org

Valley Children's Hospital is one of the nation's largest pediatric hospitals located in Central California. Our facility includes our Genetics and Maternal Fetal Center.

ATTENDANCE VERIFICATION CODES

In place of badge scanners, an attendance verification code (AVC) is provided in each session to verify attendance. Please use this page to record the AVC for each session you attend. You will be required to enter an AVC for each session you attend to complete an evaluation and claim CEUs.

See page 4 for additional instructions for evaluating sessions and claiming CEUs.

Tip: Looking for a way to collect these AVCs quickly? Take a picture of the AVC session sign – available at the back of each session room!

SESSION	ATTENDANCE VERIFICATION CODE
A01	
A02	
A03	
A04	
A05	
A06	
A07	
A08	
A09	
B01	
B02	
B03	
B04	
B05	
B06	
B07	
B08	
B09	
B10	
B11	

SESSION	ATTENDANCE VERIFICATION CODE
B12	
B13	
B14	
B15	
B16	
B17	
B18	
B19	
C01	
C02	
C03	
C04	
C05	
C06	
C07	
C08	
C09	
C10	
C11	
C12	

SESSION	ATTENDANCE VERIFICATION CODE
C13	
C14	
C15	
C16	
D01	
D02	
D03	
D04	
D05	
D06	
D07	
D08	
D09	
D10	
D11	
D12	
D13	

Quest Diagnostics™

When it comes to excellence in genetics, we deliver

Our advanced genetic testing solutions in neurology, women's health, and oncology help you make accurate diagnoses, guide targeted patient management, and provide important familial implications—because the more you know, the more you can do.

Learn more about how Quest Diagnostics is helping advance the science of genomics by attending one of more than a dozen presentations by our genetic counselors during the NSGC's 2016 Annual Education Conference. Highlights include:

When hoofbeats mean horses: new insights into the science and personal impact of diagnosing and treating alzheimer's disease
Susan Hahn, MS, CGC, Neurogenetic Outreach Specialist
Thursday, September 29, 1:30-3:00 pm, Room B16

Genetic counselors in emerging roles
Steven Keiles, MS, LCGC, Director, Genetic Counselor Organization
Friday, September 30, 5:00-5:45 pm, Room C15

To see a complete list of Quest Diagnostics speakers at the NSGC, visit **QuestDiagnostics.com/2016NSGCPresentations**

See us at the NSGC 2016 Annual Education Conference, Booth 817

1.866.GENE.INFO
(1.866.436.3463)

NOTES

ACMG...Be a Part of It

Education for Your Professional Development

ACMG provides a full range of learning experiences from introductory content for students to advanced practice education for medical genetics professionals. Learn in the environment that meets your needs; attend live conference and training events or access CME anywhere using our Genetics Academy site for online webinars, learning modules and recorded content.

Visit **www.acmg.net/education** to start your learning experience today.

Save The Dates:

2017 Annual Meeting | March 21–25 | www.acmgmeeting.net
2017 Genetics and Genomics Review Course | May 4–7 | www.acmg.net

Collaborate and Share Your Knowledge and Expertise – Network, Volunteer, Comment, Advocate

- Network with medical genetics professionals from around the world through our LinkedIn, Facebook and Twitter pages.
- Connect with the leaders in medical genetics by joining an ACMG committee, workgroup or special interest group.
- Take action – look for ACMG Advocacy alerts or visit our Advocacy page and help with our public policy activities.
- Respond to our email alerts asking for input on draft ACMG standards and guidelines.

Products, Tools and Resources to Help Your Practice, Lab or Career

- **ACMG/NBSTRN** connects researchers to essential tools with the Longitudinal Pediatric Data Resource (LPDR), the Laboratory Performance Database (R4S) and the Virtual Repository of Dried Blood Spots (VRDBS). Visit www.nbstrn.org to learn more.
- **ACMG ACT Sheets Mobile App** is available to download on Apple and Android devices, a clinical decision support tool that informs clinicians about genetic conditions.
- **ACMG's National Coordinating Center for the Regional Genetic Services Collaboratives** seeks to improve the availability, accessibility, and quality of genetic services for individuals with, or at risk, for genetic conditions and their families. Visit nccrcg.org to learn more about the NCC and your Regional Collaborative.
- ***Genetics in Medicine***, the ***ACMG in Action*** electronic newsletter and ***The ACMG Medical Geneticist*** magazine provide members with timely research, industry news, tools, advocacy updates and resources.
- **ACMG ICD-10 Pocket Guides** and **The ACMG Salary Survey** provide Genetics professionals with genetic services coding and compensation standards within the field.
- **Find a job or list an opening** on the ACMG Employment Resource Center at http://careers.acmg.net/.

ACMG...BE A PART OF IT

Learn more today! Visit www.acmg.net

ACMG
American College of Medical Genetics and Genomics
Translating Genes Into Health®

National Society of Genetic Counselors

36th Annual Education Conference

September 13-16, 2017

Greater Columbus Convention Center
Columbus, OH

RESEARCH PSYCHOSOCIAL
PRENATAL COUNSELING/ULTRASOUND ANOMALIES
PEDIATRICS **EDUCATION** POLICY DEVELOPMENT/ ADVOCACY TECHNOLOGY
ACCESS & SERVICE DELIVERY PROFESSIONAL ISSUES
HEALTHCARE CONSULTING **COUNSELING** NEURO GENETICS
FETAL INTERVENTION & THERAPY
FAMILIAL CANCER RISK COUNSELING GENETIC & GENOMIC TESTING
PSYCHIATRIC DISORDERS ASSISTED REPRODUCTIVE TECHNOLOGIES/INFERTILITY
PUBLIC HEALTH **GENOMICS** DIAGNOSTIC LABORATORIES METABOLIC **HEMATOLOGY** GENETICS
CARDIOVASCULAR GENETICS PERINATAL PHARMACEUTICAL INDUSTRY PERSONALIZED MEDICINE
MARKETING/PRODUCT DEVELOPMENT
CLIENT-CENTERED COMPETENCIES
PSYCHO SOCIAL
PEDIGREES
SERVICE DELIVERY MODELS
CASE MANAGEMENT
INFORMATION ACTIVE LISTENING DECISION-MAKING
CONTRACTING
DISEASE RISK
MEDICAL SKILLS
FAMILY HISTORY

Call for Speakers:
October 25, 2016 – January 9, 2017

Call for Abstracts:
February 1 – May 4, 2017



• GROWING OUR PROFESSION TO NEW HEIGHTS •